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SUMMARY 
Dendritic cell (DC) based vaccines rely on the quality of DC maturation to induce antigen 
presentation, co-stimulation, lymph node migration and the release of heterodimeric IL-
12p70 in case of T helper type-1 cell (Th1) polarization. In contrast, DCs that cannot 
secrete IL-12p70 (e.g. after cytokine cocktail maturation) readily induce Th1 cells when 
injected into mice and humans. Since it was also previously suggested that DCs are 
capable of activating other DCs in a bystander fashion, we tested here for the DC source 
of IL-12p70 for Th1 polarization in a murine DC vaccination model. Migration of the 
injected murine bone marrow-derived DCs (BM-DCs) was essential for antigen delivery 
to the lymph node. However, they contributed only partially to antigen presentation, and 
induced a non-polarized Th0 state of the cognate T cells producing IL-2 but no IFN-. 
Instead, endogenous dermal migratory XCR1+ cDC1s underwent re-programming by the 
injected BM-DCs to acquire bystander antigen presentation and IL-12 release for Th1 
polarization in the lymph node. Genetic deficiency of migratory DCs and specifically of 
XCR1+ migratory DCs completely abolished Th1 priming. The kinetic of cell interactions 
in the draining lymph nodes appeared step-wise as i) injected DCs with cognate T cells, 
ii) injected DCs with bystander XCR1+ DCs, and iii) bystander XCR1+ DCs with T cells. 
The transcriptome of the bystander DCs showed a down-regulation of Treg and Th2/Th9 
inducing genes, and up-regulation of genes required for Th1 instruction. Together, these 
data show that injected mature lymph node migratory BM-DCs direct T cell priming and 
bystander DC activation, but not Th1 polarization which is mediated by endogenous IL-
12p70+ XCR1+ migratory bystander DCs. Our results are of importance for clinical DC-
based vaccinations against tumors where endogenous DCs may be functionally impaired 
by chemotherapy. 
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ZUSAMMENFASSUNG 
Auf Dendritische Zellen (DCs) basierende Vakzinen hängen von der Qualität der DC-
Reifung ab, um Antigenpräsentation, Kostimulation, Lymphknotenmigration und, im Faller 
einer T-Helfer-1 (Th1) Polarisierung, die Freisetzung von IL-12 zu induzieren. Die 
Herstellung des heterodimeren IL-12p70 durch injizierte DC wurde klassisch als 
Schlüsselfaktor beschrieben, der für die Erzeugung einer polarisierten Th1 
Immunreaktion erforderlich ist. Dennoch induzieren DCs, die IL-12 nicht ausscheiden 
können (z. B. nach Reifung des Cytokin-Cocktails), Th1 polarisierte Immunantwortenin 
Mäusen und Menschen. Da zuvor auch beschrieben wurde, dass DCs in der Lage sind, 
andere DCs auf Bystander-Weise zu aktivieren, haben wir hier die DC-Quelle der IL-12 
Produktion für die Th1-Polarisation in einem murinen DC-Vakzinemodell untersucht. Die 
Migration der injizierten, aus murinem Knochenmark generierten DCs (BM-DCs) war für 
den Antigentransport in den Lymphknoten wesentlich. Sie trugen jedoch nur teilweise zur 
Antigenpräsentation bei und induzierten nur einen nicht polarisierten Th0-Zustand der T-
Zellen, die IL-2 produzierten, aber kein IFN-. Stattdessen deuten die Daten daraufhin, 
dass endogene dermale migrierende XCR1+ DCs als Bystander-DCs zur 
Antigenpräsentation beitragen und IL-12 für die Th1 Polarisation bereitstellten. Die 
genetische Ablation von migrierenden DCs und speziell von XCR1+ migrierenden DCs 
hebt das Th1 Priming vollständig auf, Die Kinetik der Wechselwirkungen in den 
drainierenden Lymphknoten erfolgt schrittweise, indem i) injizierte DCs mit verwandten 
T-Zellen, ii) injizierte DCs mit Bystander XCR1+ DCs und iii) Bystander XCR1+ DCs mit 
T-Zellen in Kontakt treten. Das Transkriptom der Bystander-DCs zeigte eine 
Herunterregulierung von Treg- und Th2/Th9-induzierenden Genen und eine 
Hochregulierung der für die Th1- Induktion erforderlichen Gene. Zusammen zeigen diese 
Daten, dass injizierte reife migrierende BM-DCs das T-Zell-Priming und die Bystander-
DC-Aktivierung steuern, nicht jedoch die Th1-Polarisation, die durch endogene IL-12p70+ 
XCR1+ Bystander-DCs vermittelt wird. Unsere Ergebnisse sind von Bedeutung für 
klinische Studien mit Vakzine-DCs, bei denen endogene DCs durch eine Chemotherapie 
funktionell beeinträchtigt werden können.  
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1 INTRODUCTION 
 1.1 Innate immune response  
The innate immune response acts as the first line of defense protecting us from invading 
pathogens. It consists of cellular and biochemical defense mechanisms that can detect 
and destroy microbial invaders within minutes or hours. This is done using a limited 
number of secreted proteins and cell-associated receptors that are encoded by intact 
genes inherited through the germline to detect infection and to distinguish between 
pathogens and host tissues. These receptors are called pattern recognition receptors 
(PRRs). They can recognize structures exclusively present on and shared by microbes, 
which are called pathogen-associated molecular patterns (PAMPs), and endogenous 
danger-associated molecular patterns (DAMPs) which are molecules released by 
stressed cells undergoing necrosis. These act as danger signals promoting and 
exacerbating the inflammatory response. They are often essential structures for survival 
of the microbes, thus limiting the capacity of microbes to evade detection by mutating or 
losing expression of these molecules. PRRs include receptors present on the cell surface 
and in endosomes such as Toll-like receptors (TLRs), recognizing a wide variety of 
ligands, including bacterial cell wall components and microbial nucleic acids. Also, 
cytoplasmic pattern recognition receptors that recognize microbial molecules such as the 
RIG-like receptors (RLRs), which recognize viral RNA, and the NOD-like receptors 
(NLRs), which activate the inflammasome and are involved in the response against 
several pathogens, inflammatory diseases, cancer, metabolic and autoimmune disorders 
(Takeuchi and Akira, 2010). 
The principal components of innate immunity are (1) anatomic barriers including physical 
and chemical barriers, such as cilia, and mucus membranes. Also epithelial cells 
secreting antimicrobial peptides such as defensins that directly lyse bacterial cell 
membranes, or enzymes such as lysozyme that can digest bacterial cell wall; (2) 
phagocytes such as neutrophils, macrophages, dendritic cells, natural killer (NK) cells, 
and lymphocytes with invariant antigen receptors that act directly by engulfing and 
digesting invading microorganisms; (3) blood proteins, including members of the 
complement system that targets pathogens both for lysis and for phagocytosis by cells of 
the innate immune system; and (4) cytokines that regulate and coordinate many of the 
activities of the innate immune system (Turvey and Broide, 2010). Such cytokines include: 
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TNF and IL-1 that activate endothelial cells, stimulate chemokine production, and 
increase neutrophil production by the bone marrow (BM). IL-1 and TNF induce IL-6 
production, and all three cytokines mediate systemic effects, including fever and acute-
phase protein synthesis by the liver (Heinrich et al., 1990). IL-12 and IL-18 stimulate 
production of the macrophage activating cytokine IFN- by NK cells and T cells (Tominaga 
et al., 2000). These cytokines function in innate immune responses to different classes of 
microbes and modify adaptive immune responses that follow the innate immune 
response. Adaptive immunity can recognize a much broader range of substances and, 
unlike innate immunity, displays memory of antigen encounter and specialization of 
effector mechanisms. 
 
 1.2 Adaptive immune response 
Almost all types of infections require the concerted action of both innate and adaptive 
immunity.  There are two types of adaptive immune responses, which are humoral 
immunity and cell-mediated immunity. Both are mediated by different components of the 
immune system and cooperate in eliminating different types of microbes (Bonilla and 
Oettgen, 2010).  
The humoral immune response serves to protect the extracellular spaces, where 
antibodies produced by B cells destroy extracellular microorganisms and their products 
and prevent the spread of intracellular infections. Antibodies can bind to pathogens and 
prevent them from entering and infecting cells, thus they are said to neutralize the 
pathogen; they also bind bacterial toxins to prevent their action or their entry to the cell. 
Another function they serve is opsonization which is the uptake of the pathogens by 
phagocytes. This happens by binding to Fc receptors on phagocytes through their 
constant regions (C regions). Finally, they can activate proteins of the classical pathway 
of the complement system when they are bound to pathogens. This enhances the 
opsonization process by other complement proteins placed on the surface of pathogens, 
recruit phagocytes to the infection site, and activate the so-called membrane-attack 
complex, which directly lyse certain pathogens by inducing pore-formation on their 
surface. The humoral immunity chooses which effector mechanism to use based on the 
heavy-chain isotype of the produced antibodies (Lu et al., 2018). 
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Cell-mediated immunity is initiated upon encounter of naive T cells with a specific antigen 
on the surface of antigen-presenting cells (APCs) in the T-cell zones of secondary 
lymphoid organs (SLOs). In most cases, APCs responsible for activating naive T cells 
and inducing their clonal expansion, are dendritic cells that express the co-stimulatory 
molecules B7-1/CD80, and B7-2/CD86 (Freeman et al., 1993). This activates T cells and 
make them produce IL-2 (Freeman et al., 1993), which is an important cytokine 
modulating early proliferation and differentiation of T cells (Ross and Cantrell, 2018). After 
recognizing a specific antigen and receiving co-stimulatory signals, the T cells are in a 
stage termed Th0, previously observed in mouse T cell clones, where IL-2 production by 
the T cells can be measured but no fully polarized Th cytokine restriction is observed 
(Firestein et al., 1989; Openshaw et al., 1995). T cells are classified based on the 
expression of two surface markers, which are CD4 and CD8 (Miceli and Parnes, 1991). 
CD8 cytotoxic T cells (CTLs) kill target cells upon the recognition of the specific foreign 
antigen, which their T cell receptor (TCR) can bind to, presented on the major histo-
compability class I molecule (MHC I) of virus or bacteria-infected cells. They also 
recognize tumor cells expressing tumor-induced neoantigens on MHC I molecules (Zhang 
and Bevan, 2011). CD4 T cells enhance the effector functions of CTLs but also of the 
innate immune response and are thus called helper T cells. They can recognize foreign 
antigens presented on MHC class II molecules which are resent exclusively on 
professional APCs such as dendritic cells (Zhu and Paul, 2008). Additionally, a distinct 
subset of CD4 T cells, termed regulatory T cells (Tregs), can serve to help control and 
limit immune responses by suppressing immunogenic T-cell activity (Vignali et al., 2008; 
Zhu and Paul, 2008).  
 
 1.3 Dendritic cells 
DCs are BM‐derived or embryo-derived cells that are found in blood and lymphoid organs 
(Banchereau and Steinman, 1998; Wang et al., 2012). They were originally identified by 
Ralph Steinman and Zanvil Cohn in mouse spleen based on their unique stellate 
morphology, which distinguished them from macrophages (Steinman and Cohn, 1973). 
Subsequently, they were found to be the most potent stimulators of naive T cells in mixed 
lymphocyte reactions, this set the foundation for decades of research that showed the 
importance of DCs in initiating and propagating adaptive immune responses (Steinman 
et al., 1983). Their main function is to bridge the innate and adaptive immune systems. In 
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this sense they act as central regulators of the entire immune response, responsible for 
both sensing the nature of the threats faced and activating the precise combination of 
effector mechanisms to eliminate such threats. DCs are innate immune cells because 
they recognize and respond to PAMPs and DAMPs, thus shaping the acute inflammatory 
response. The way they bridge to the adaptive immunity is by processing extracellular 
and intracellular proteins and present them as peptide antigens in the context of MHC 
molecules to prime naive T cells. Also, they are considered as critical modulators of both 
thymic and peripheral immune tolerance. This was demonstrated in several transgenic 
mouse models, where eliminating DCs was sufficient to break immune tolerance and 
induce autoimmune pathologies (Audiger et al., 2017; Hasegawa and Matsumoto, 2018).  
Based on the different cytokines and transcription factors that drive the development of 
DCs and on the surface markers they express; DCs are a heterogenous mixture of cells 
that share a common origin but differ in their development and function (Dudziak et al., 
2007; Guilliams et al., 2016; Merad et al., 2013). Upon completing their differentiation, 
they are all characterized by the expression of the integrin CD11c and MHC II molecules. 
These are considered as universal markers for DC identification, though their expression 
level varies depending on the subset. DCs that were originally identified by Steinman in 
the spleen are termed conventional DCs (cDCs) as they were the first DCs identified 
(Steinman and Cohn, 1973). Later a population of cells that morphologically resemble 
plasma cells but produce large amounts of IFN- upon viral stimulation were identified 
and are thus termed plasmacytoid DCs (pDCs) (Colonna et al., 2004). Another subset 
arises from monocytes under inflammatory conditions and is termed monocyte derived 
DCs (MoDCs) (Lutz et al., 2017).  
 
 1.4 Dendritic cell lineage and development 
cDCs arise from hematopoietic lineages that are different from other immune cells. The 
first early committed progenitors defined in mice and human are common lymphoid 
progenitors (CLPs) and common myeloid progenitors (CMPs) (Akashi et al., 2000; Kondo 
et al., 1997). The identification of progenitors of certain immune cells from other 
hematopoietic lineages relied mainly on adoptive transfer studies of irradiated animals 
that carry elevated levels of circulating cytokines. Many groups are now validating such 
studies using genetic fate-mapping of these clonogenic progenitors in the steady state. 
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The adoptive transfer of CLPs and CMPs into irradiated animals mainly produced cDCs 
and pDCs (Traver et al., 2000). Similar potential was also found for human CLPs and 
CMPs cultured in vitro. The maintenance of cDC developmental potential from 
hematopoietic progenitors was strictly linked to the expression of the tyrosine kinase 
receptor Fms-like tyrosine kinase 3 (Flt3), the ability of the progenitors to respond to its 
ligand, Flt3L, and the downstream signaling factor STAT3 (Naik et al., 2005). Flt3L or Flt3 
deficient mice showed a dramatic loss of pDCs and cDCs in the spleen and lymph nodes 
(LNs), and in peripheral tissue (McKenna et al., 2000). Later it was shown that CLPs and 
CMPs are heterogenous for Flt3 expression and only Flt3+ fractions were capable of 
generating DCs (Karsunky et al., 2003). Most of the steady-state cDCs however are of 
myeloid origin as it was shown that CMPs vastly outnumber CLPs. CMPs are defined by 
being (CD117+) cKithi, CD34+, CD16/32+, Sca1− . They give rise to monocyte and DC 
committed precursors (MDPs) (Fig 1) that lose their capacity to differentiate to 
granulocytes (Fogg et al., 2006). MDP failure to give rise to granulocytes depends on 
expression of the transcription factor interferon (IFN) regulatory factor 8 (IRF8) (Becker 
et al., 2012). These progenitors are Lin−, Sca−, Kithi, Flt3+, (M-CSFR+) CD115+, 
CX3CR1+ and lack lymphoid, megakaryocyte, and granulocyte development potential but 
can differentiate to monocytes, macrophages and DCs. MDPs give rise to the common 
dendritic progenitor (CDP) (Fig 1) which remain CD115+ (M-CSFR+), CD135+ (Flt3+), and 
express high levels of IRF8 which is critical for their survival and continued development. 
CDPs lack monocyte differentiation capacity and subsequently move towards a pDC or 
cDC fate (Liu et al., 2009; Onai et al., 2007). A CDP-derived clonogenic pre-DC population 
that gives rise to cDCs was identified first in lymphoid tissues, and later found in blood, 
which populates lymphoid organs via the circulation and gives rise to cDCs in both 
lymphoid and nonlymphoid tissues. This population differentiates in the BM and can be 
classified into four different subsets along their development axis based on the expression 
of the surface markers Ly6C which is a GPI-linked surface protein and Siglec H which is 
a CD33-related siglec family member or alternatively CD117 and transcription factor 
Zbtb46 expression. Siglec H+ Ly6C- pre-DCs are the developmentally earliest cells 
differentiating from CDPs. If they are Siglec H+ andLy6C+ they lose their potential to 
develop into pDCs and leave the BM giving rise eventually to cDCs (Fig 1) (Schlitzer et 
al., 2015). If they stay in the BM, they develop into pre-pDCs which are Flt3+ but lack M-
CSFR expression and eventually give rise to mature IFNα-secreting pDCs (Fig 1) that 
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depend on the helix-loop-helix transcription factor E2-2 (also known as TCF4) for their 
development (Cisse et al., 2008; Onai et al., 2013). pDCs leave the BM to go to the 
lymphoid organs and peripheral blood upon completing development (O'Keeffe et al., 
2003). cDC precursors that leave the BM travel through the blood and enter SLOs and 
other tissue, differentiate under yet-unknown cues into two subsets: pre-cDC1 which are 
Siglec H- and Ly6C- and give rise to conventional type 1 DCs (cDC1) characterized by 
CD8α or CD103 and the chemokine XC receptor (XCR1) expression, and pre-cDC2 which 
are Siglec H- Ly6C+ and are dedicated precursors to conventional type 2 DCs (cDC2) 
characterized by CD4 and CD11b expression (Fig 1)  (Merad et al., 2013). This allows an 
additional level of tissue-specific regulation of DCs that enables organ- and niche-specific 
functional adaptation. cDC subsets will be described in more details in a subsequent 
chapter. cDCs are generally short-lived and are constantly being replaced by precursors 
from the BM every 3 to 6 days in a Flt3L-dependent manner (Guilliams et al., 2016; Merad 
et al., 2013). The transcription factors Ikaros (Wu et al., 1997), PU.1, Gfi1 (Rathinam et 
al., 2005) and CbfB (Satpathy et al., 2014) were also shown to control the development 
of DC lineages. PU.1 drives Flt3 expression at later stages of DC development and is 
involved in expression of IRF8 as early as the CMP or MDP (Carotta et al., 2010). 
Recently, the transcription factor Bcl11a was shown to also drive Flt3 expression and is 
required for all DC subsets development (Ippolito et al., 2014). Bcl11a is required for IL-
7 receptor expression which is not only required for T and B cell development but also for 
DC development (Vogt et al., 2009).  
MDPs can also differentiate to common monocyte progenitors (cMoPs) characterized by 
being Lin-, CD117+ (c-Kit+), CD115+ (M-CSFR+), CD135- (Flt3-), Ly6C+, which strictly 
derive monocytes. Under inflammatory conditions monocytes can give rise to monocyte 
derived DCs (MoDCs) which can be developed using IL-4 and Granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Fig 1) (Sallusto and Lanzavecchia, 1994) and lack 
the expression of the transcription factor ZBTB46 and is characterized by histone H4K16 
acetylation that does not take place in monocytes and macrophages (Lutz et al., 2017; 
Nicholas et al., 2015). In addition to cDCs and MoDCs, Langerhans cells (LCs) are 
another subset of DCs that has been described as the prototypical DC. They are sentinel 
tissue-resident DCs that populate the epidermal skin layer and migrate to skin-draining 
LNs to activate naive T cells upon activation. Unlike cDCs, LC development is 
independent of Flt3L but requires (M-CSFR+) engagement though not by Csf1, but rather 
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its alternative ligand IL-34 and arise from embryonic monocytic precursor cells (Fig 1) 
(Wang et al., 2012). This caused an intense debate about whether LCs are true DCs or 
are more closely related to tissue-resident macrophages (Lutz et al., 2017). 
 
Figure 1: The development and defining markers for the different DC subsets including cDC1s, cDC2s, pDCs, LCs, and MoDCs 
 
1.5 DC migration 
DCs have been called professional antigen-presenting cells because of their potent ability 
to prime naive T cells. Much of this ability stems from their unique migratory pattern. 
Unlike most innate sentinel cells, upon encountering a viral or bacterial pathogen, 
activated DCs leave the infected area and migrate towards the draining LNs. As naive T 
cells can only access SLOs, they rely on this sentinel function of DCs for responding to 
the presence of an infection. The migratory pattern of DCs from peripheral tissues to and 
within SLOs has been well studied for decades, but a coherent set of rules for how these 
migratory journeys impact the most important roles for DCs, T cell priming and 
differentiation, is only now becoming clear (Calabro et al., 2016). 
DCs are strategically positioned at ports entering the organs such as the splenic marginal 
zone and at different physical body barriers such as the skin or mucosa. Efficient 
directional migration of cDCs toward T cell zones within lymphoid organs or towards 
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distant draining LNs is required to ensure efficient stimulation of naive T cells. Peripheral 
cDC migration via afferent lymphatics depends on the chemokine receptor CCR7 and 
utilize CCL19 and CCL21 which are the same migratory cues that T cells use to enter the 
LN (Forster et al., 1999; Teijeira et al., 2014). Immobilized CCL21 on lymphatic 
endothelium plays a critical role in facilitating the chemotaxis and arrest of migrating 
tissue DCs to enter the afferent lymphatics (Tal et al., 2011). Complementary roles in cDC 
migration have been suggested for other chemokine receptors such as CXCR4 and its 
ligand CXCL12, but CCR7 seems to be the major player (Kabashima et al., 2007). Intra-
tissue migration of lymphoid organ-resident cDCs, although seemingly also CCR7 
dependent, remains less well understood. It is important to note that Ccr7-/- mice have an 
abnormal development and compartmentalization of immune cells within the LN (Ohl et 
al., 2003). Other chemokines have been described for the migration of DCs within 
lymphoid and non-lymphoid tissues. For example, splenic CD11b+ cDC2s are recruited 
to the bridging channels of the marginal zone by the chemotactic receptor EBI2 (Gatto et 
al., 2013), while the CCR6-CCL20 axis controls the migration of DCs toward the mucosal 
surfaces within the Peyer’s patch (Cook et al., 2000). XCR1 expression on cross-
presenting DCs has been shown to orchestrate their intra-tissue positioning in the thymus 
(Lei et al., 2011) and more recently , their recruitment to CD8+ T cells expressing the 
XCR1 ligand XCL1 during viral immune response (Brewitz et al., 2017). On the other 
hand, the egress of monocytes from the BM under inflammatory conditions and the 
subsequent arrival into the skin dermis where they can be converted into MoDCs is 
mediated by CCR2 together with the help of CCR5 (Nagao et al., 2012). While the 
migration of DCs from peripheral tissues to draining LNs are extensively studied, the 
molecular cues required for the immigration of DCs from the BM and from blood to 
lymphoid and non-lymphoid tissues is unfortunately still poorly understood. 
 
 1.6 Dendritic cell subsets 
1.6.1 CD103+ and CD8+ dendritic cells 
cDC1s can be found in both the spleen and LNs but also as tissue-resident DCs that 
migrate to draining LNs upon receiving a pathogen or a danger signal, and they also 
migrate under steady-state conditions to deliver self-antigens for tolerance induction. Both 
subsets are defined by their unique expression of XCR1 but are distinguished from each 
other by the expression of CD11c and MHC II molecules and by the integrin marker 
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CD103 (ITGAE) and CD8+ expression. Lymphoid resident cDC1s are CD8high CD11chigh 
CD103low and MHC IIint, while migratory cDC1s are CD8αlow CD11cint CD103high and MHC 
IIhigh. CD8α+ lymphoid resident DCs express the CD8α transcript and protein, but not 
CD8αβ, which is most commonly expressed by CD8+ T cells (Shortman and Heath, 2010). 
CD103+ cDC1s that reside in the dermis also express the C-type lectin langerin (CD207) 
which is involved in the formation of the intracytoplasmic Birbeck granules (Kissenpfennig 
et al., 2005). 
cDC1s represent 20–40% of spleen and LN cDCs. In contrast, they constitute most of the 
thymic cDC population and are generated locally from early thymocyte progenitors. They 
express distinct lectin and TLRs compared to CD11b+ cDC2s. Lectin receptors include 
CD205, and Clec9A, and langerin which are expressed mostly by cDC1s (Jiang et al., 
1995), in contrast to DC immunoreceptor 2 (DCIR2) expressed exclusively by CD11b+ 
DCs. These receptors have been exploited for targeted delivery of antigens to specific 
DC subsets. They also lack macrophage markers such as CD11b, CD115, CD172a, 
F4/80, and CX3CR1 (Ginhoux et al., 2009). Until now cDC1s are considered the best-
characterized cDC subset, both by their phenotype and their gene expression signature, 
and they also appear to be an evolutionary conserved subset. They are distinguished by 
being the most efficient cross-presenters of foreign antigens such as viral and tumor 
antigens on MHC I molecules to CD8+ T cells, though unlike in mice, CD11b+ DCs were 
shown to also possess cross-presentation capacity in humans (Segura et al., 2013).  
TLR stimulation on CD8a+ and CD103+ cDC1s induces prominent secretion of the 
bioactive IL12p70 (Reis e Sousa et al., 1997). It is worth noting that in contrast to 
macrophages, IL-12 production by CD8α+ and CD103+ cDC1s requires c-Rel (Grumont 
et al., 2001). Their development is orchestrated by the same set of transcription factors: 
IRF8; which is required for the development of all cDCs from their BM precursors as 
discussed before, inhibitor of DNA binding 2 (Id2), basic leucine zipper ATF-like 3 
transcription factor (BATF3), and the nuclear factor interleukin 3 regulated (NFIL3). 
Knockout models of either of these genes results in a severe developmental defect of 
CD8α+ and CD103+ cDC1s, but not CD11b+ cDC2s. The hierarchy and sequential 
involvement of these specific transcription factors within the CD8α and CD103 cDC 
lineage is emerging (Murphy et al., 2016). While IRF8 seems obligatory for the 
development of Id2-expressing DC precursors, BATF3 is induced at later stages of CD8α 
and CD103 cDC1 maturation (Hildner et al., 2008). Indeed, cDC1 development can be 
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observed in BATF3-deficient mice infected with intracellular pathogens or treated with IL-
12, this appears to be dependent on compensatory BATF and BATF2 expression 
(Tussiwand et al., 2012). Additionally, short-term development of cDC1s was observed in 
the absence of Id2, NFIL3, and BATF3, which collectively suggests that IRF8 is the 
master regulator of CD8a and CD103 cDC1 development (Seillet et al., 2013). 
 
1.6.2 CD11b+ dendritic cells 
CD11b+ cDCs (cDC2s) are the most abundant cDCs in lymphoid organs except for the 
thymus, representing 50-60 % of spleen and LN cDCs, and can also be found as 
migratory cells in nonlymphoid tissue. They are separated by the differential expression 
of CD11c and MHC II as described for CD8α and CD103 cDC1s. However, in contrast to 
CD8 and CD103 DC1s, the population currently defined as CD11b+ cDC2s is 
heterogeneous and remains less well characterized. Like cDC1s, cDC2s proliferate in situ 
in response to Flt3L, and are reduced in Flt3-and Flt3L-deficient mice, though to a lesser 
extent compared to cDC2s. They can be identified by expression of surface markers 
CD11b, DCIR2 (by staining with the antibody 33D1), CD301b (MGL2), CD4 or signal 
regulatory protein-α (SIRPα), depending on the tissue investigated (Suzuki et al., 2004). 
The transcription factors controlling general CD11b+ cDC2 development include RelB 
(Briseño et al., 2017), NOTCH2 (Lewis et al., 2011), RBP-J (Caton et al., 2007), IRF2 
(Ichikawa et al., 2004), and IRF4 (Suzuki et al., 2004). It is worth noting that IRF4 also 
controls functional aspects of CD11b+ DCs, such as their MHC presentation capacity 
(Vander Lugt et al., 2014) and migration (Bajana et al., 2012; Gao et al., 2013). However, 
deficiencies of IRF4 and NOTCH2 only partially impair this compartment and this 
impairment is variable in different tissues (Bajana et al., 2012; Lewis et al., 2011). Given 
the heterogeneity of this subset, it is not surprising that assigning specific functions to 
cDC2s is still a daunting task, and in most of the cases, CD11b+ DCs are still defined by 
absence of cDC1 associated-functions. For instance, their inability to cross-present and 
produce specific cytokines, such as IL-12 compared to cDC1s. It was observed though 
that cDC2s are superior in the induction of CD4+ T cell immunity compared to cDC1s, 
potentially due to their superior of MHC-II presentation capacity (Dudziak et al., 2007; 
Lewis et al., 2011). They are also characterized by a distinct cytokine secretion profile, 
such as IL-6 (Persson et al., 2013) and IL-23 (Schlitzer et al., 2013b). Also, splenic cDC2s 
were shown to be major producers of proinflammatory chemokines such as CCL3, CCL4, 
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and CCL5 (Proietto et al., 2004) after TLR ligand exposure. The in vivo relevance of these 
activities is yet to be determined. 
cDC2s in the spleen can be sub-classified based on the differential expression of the 
endothelial cell–specific adhesion molecule (ESAM). ESAMhiCD11b+ DCs seem to 
depend of Notch2 expression and are defined by higher CD4, CD11c, and Flt3 levels and 
lower Csf-1R, Csf-3R, and CCR2 levels than do ESAMloCD11b+ DCs. 
ESAMhiCD11b+ splenic DCs derive from DC-restricted precursors and are dependent on 
Notch2 signaling (Lewis et al., 2011), whereas ESAMloCD11b+DCs are thought to derive 
from circulating monocytes and are dependent on Kruppel Like Factor 4 (Klf4) signaling 
(Tussiwand et al., 2015).  
 
1.6.3 CD8- CD11b- (DN) dendritic cells 
Another DC subset that remains poorly characterized are CD8- CD11b- (DN) DCs 
(Iwasaki and Kelsall, 2001; Proietto et al., 2004). They constitute around one-third of all 
DCs in Peyer’s patch, around 30% in the mesenteric LN and only a minor and indistinct 
population in the spleen (9%) and peripheral lymph nodes (13%) (Iwasaki and Kelsall, 
2001). Among splenic cDCs, they were shown to express moderate amounts of CCR6 
(Iwasaki and Kelsall, 2000) and, under inflammatory conditions they upregulate the 
chemokines CCL3, CCL4, and CCL5 (Proietto et al., 2004). They responded specifically 
to R848 (a TLR-7 agonist) and CpG (a TLR-9 agonist) among a panel of tested TLR 
stimuli (Proietto et al., 2004). In vitro stimulation of DN DCs was shown to induce DEC-
205 expression, but they remain negative for the CD8 and CD11b markers indicating that 
this subset does not represent an immature stage of cDC1s or cDC2s (Iwasaki and 
Kelsall, 2001). In human DCs, CD141+ DCs correspond to mouse CD8+ cDC1s and 
CD1c+ DCs correspond to mouse CD11b+ cDC2s. A CD141- cDC1- DC subset is also 
identified in human peripheral blood mononuclear cells (PBMCs) (Villani et al., 2017). 
More recently, they were also shown to be significantly higher in squamous cell tonsillar 
cancer biopsies compared to their counterparts in benign tonsils (Abolhalaj et al., 2018) 
 
1.6.4 Plasmacytoid dendritic cells 
pDCs are blood-circulating DCs that are found only as a small population throughout the 
periphery and in lymphoid organs. They characteristically have a highly developed 
secretory compartment and are recognized by the expression of CD45R (B220), Ly6C, 
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and the transmembrane glycoprotein PDCA-1 (CD317) in mice and CD123, 
CD303/BDCA2, and CD304/BDCA4 in humans. They have a distinct morphology but they 
share many cDC characteristics such as Flt3L dependency (Kingston et al., 2009), and 
an ability to prime T cells though in a more restricted manner (Sapoznikov et al., 2007). 
Also, their transcription profile overlaps with cDCs but is quite distinct (Robbins et al., 
2008). They selectively express Toll-like receptor 7 (TLR7) and TLR9, and as such their 
most important function is thought to be producing large quantities of type 1 IFNs in 
response to single-stranded viral RNA and DNA, a direct consequence of their 
constitutive IRF7 expression (Honda et al., 2005). E2-2 transcription factor that is required 
for their development mediates that by direct suppression of Id2 expression that is 
required for CD8 and CD103 cDC1 development (Ghosh et al., 2010). This has been 
confirmed by early deletion of E2-2, which leads to a complete absence of pDCs both in 
human and mouse (Cisse et al., 2008). While excision of the E2-2 gene in mature pDCs 
initiated an alternative cDC transcription program shifting them towards CD8 
development (Ghosh et al., 2010). Such ‘‘converted’’ CD8+ pDCs bear D-J 
rearrangement indicative of their pDC past and are discriminated from CD8+ cDC1s by 
expression of CX3CR1 among other markers (Bar-On et al., 2010), though the 
contribution of these ‘‘ex-pDCs’’ to the immune response is yet to be shown. pDCs have 
the potential to act as APCs, since they express MHC II and co-stimulatory molecules; 
but their ability to phagocytose dead cells and present cell-associated antigen is yet to be 
clearly established, also their ability to cross-present exogenous antigen on MHC class I. 
Single-cell RNA-sequencing analysis of blood DCs coupled with functional 
characterization indicates that human pre-DCs contaminated the classically defined pDC 
gate and this contamination can be responsible for the previous misrepresentation of 
pDCs’ “T cell-activating” property (Villani et al., 2017). In tumors, pDCs seem to correlate 
with poor prognosis of both breast and ovarian cancers (Conrad et al., 2012), but they 
are also studied as potential therapeutic targets to elicit IFN-α release and antigen 
presentation by cDCs (Kranz et al., 2016; Treilleux et al., 2004).  
 
1.6.5 Langerhans cells 
LCs are described as the prototypical DCs that were first discovered in the 19th century 
and gained special attention after splenic DC discovery. They are a unique population of 
mononuclear phagocytes that are restricted to the epidermal skin layer. They were shown 
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to express high levels of MHC II and could stimulate an MLR after in vitro culture with T 
cells. Moreover, studying LCs was the first clue to understanding the distinct functional 
stages of DC maturation (Schuler and Steinman, 1985). They constitute 3–5% of 
epidermal cells, with approximately 700 LCs/mm2 (Merad et al., 2008) and are different 
from other tissue cDCs by having unique ontogeny and homeostatic properties (Ginhoux 
and Merad, 2010). As described earlier, LCs arise from fetal liver-derived monocytes 
(Wang et al., 2012), and self-renew under physiological steady-state conditions without 
replacement by blood-borne precursors (Merad et al., 2002). LCs are characterized by 
high levels of Langerin expression similar to dermal cDC1s, but they are differentiated 
from dermal cDC1s by the lack of expression of CD103, XCR1, and DEC-205 (Ginhoux 
et al., 2007). 
Murine LCs also express a specific epithelial cell adhesion molecule (EpCAM). The 
deletion of this molecule was shown to reduce mobilization of LCs and inhibit their 
tolerance induction capacity in a contact hypersensitivity mouse model (Gaiser et al., 
2012). They play important roles both in immunity and tolerance induction upon mobilizing 
to the skin draining lymph nodes. They secrete IL-6 which is essential for protecting mice 
against Candida albicans infection by promoting Th17 cell responses (Igyarto et al., 
2011). They were also shown to suppress protective immunity during Leishmania major 
infection (Kautz-Neu et al., 2011). In human LCs expression of high levels of CD1a was 
described (Ito et al., 1999). CD1c is a member of the group 1 CD1 proteins (CD1a, CD1b, 
and CD1c). This group of proteins has been shown to have the capacity to present lipid 
antigens to T cells (Hunger et al., 2004). 
 
1.6.6 Monocyte-derived DCs (MoDCs) 
MoDCs arise as a consequence of inflammation or infection and can be found in lymphoid 
and non-lymphoid organs (Serbina et al., 2003). They are derived from the monocyte 
influx induced by inflammation and as such termed ‘‘monocyte-derived DCs’’ (MoDCs) or 
‘‘inflammatory DCs’’ (iDCs) (Segura and Amigorena, 2013). The study of BM culture-
derived MoDCs using IL-4 and GM-CSF has yielded many of our insights into DC biology 
over the past decades. MoDCs are characterized by being more versatile and can 
perform functions of different DC subsets. In tissues, they can perform typical DC 
functions such as antigen presentation to effector T cells, pathogen clearance, migration 
to SLOs and cytokine production. Since they are of monocytic origin they express CD64, 
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the Fc-gamma receptor 1 (FcgRI) but also Ly6C and typical DC markers including CD11c, 
high levels of MHC II and CD11b (Lutz et al., 2017; Min et al., 2018). Though their gene 
expression profiles differ considerably from cDCs (Xu et al., 2007), they are still very 
useful in many DC studies owing to their powerful antigen presentation capacity and 
robust cytokine production. TIP DCs that appear during pathogen-associated 
inflammation (Serbina et al., 2003) have been considered the prototypic MoDCs. 
However, their pronounced proinflammatory signature and their Csf2-independent 
development might suggest that they are activated effector monocytes rather than cDC-
like cells (Greter et al., 2012). In vivo MoDCs are also DC-SIGN (CD209a)-positive DCs 
as described by (Cheong et al., 2010) where they appeared in LNs after TLR ligand 
challenge. MoDCs also appear to be more closely related to CD11b+ cDC2s. Thus, 
understanding MoDCs in vivo will probably contribute to our understanding of the 
heterogeneous CD11b+ cDC compartment. MoDCs were shown to be recruited from 
blood into lymph nodes and are differentiated from monocytes by LPS and live or dead 
gram-negative bacteria. Their mobilization requires TLR4 and its CD14 co-receptor and 
Trif. In vivo MoDCs were shown to be as capable as cDCs of antigen presentation. This 
included cross-presentation of proteins and live gram-negative bacteria on MHC I similar 
to cDC1s. After their full differentiation they required L-selectin and CCR7 for their 
migration to the T cell areas (Cheong et al., 2010). 
 
1.7 Spatiotemporal organization of DCs in LNs 
After CCR7-dependent migration from tissues, migratory DCs end up at the subcapsular 
sinus (SCS) of the LN and cross the SCS floor in a CCR7-independent manner (Braun et 
al., 2011). Migratory cDC1s and cDC2s then enter the interfollicular zone (IFZ) and home 
to the different areas of the LN (Schumann et al., 2010). An early study observed 
segregation of cDC1s and cDC2s, cDC1s were located in the deep T cell zone (TCZ) and 
cDC2s were in the T cell–B cell border (Ingulli et al., 2002). A langerin reporter mouse 
model that marks both CD103+ cDC1s and LCs migrating from the skin showed that both 
populations migrate into the deep TCZ (Kissenpfennig et al., 2005). On the other hand, 
CD11b+ migratory DCs localized to the outer paracortex (Gerner et al., 2015; 
Krishnaswamy et al., 2017). Studies using mice with knock-in photoconvertible 
fluorescent proteins to track DC migration dynamics showed that migratory cDC1s arrive 
to the skin draining LNs within 1 day after immunization but require another 24 hours to 
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reach the deep TCZ, where they are mixed with LN-resident cDC1s (Braun et al., 2011; 
Tomura et al., 2014).  
This result was also similar when imaging LNs by intravital microscopy following adoptive 
transfer of either BM-derived or splenic DCs. These transferred cells were located in the 
T cell–B cell border, proximal to HEVs, and therefore this might serve as a zone for DC 
scanning by incoming naive T cells from the circulation (Bajenoff et al., 2003; Mempel et 
al., 2004; Miller et al., 2004). Also, in lung-draining LNs; migratory cDC2s localize to the 
T cell–B cell border, while migratory cDC1s were located in the deep TCZ (Krishnaswamy 
et al., 2017). Therefore, it appears that this distribution pattern of cDC1s and cDC2s is 
conserved across a variety of tissues both at steady state and upon immunization. This 
was also mirrored in an elegant study that was conducted in human LNs; where cDC2s 
are found at the T cell–B cell border, and cDC1s at the TCZ (Granot et al., 2017). 
Studies indicate that both LN-resident cDC1s and cDC2s can acquire antigen through 
sampling of lymph after footpad or intra-auricular injection (Gerner et al., 2015). Whether 
this occurs at cortical conduits in the outer TCZ or lymphatic sinuses at the cortico-
medullary junction which is adjacent to peripheral follicles is still unknown. It was 
previously shown that LN-resident CD11b+ DCs sample small antigens that are 
transported to LN conduits after injection in the outer LN T cell–B cell border (Sixt et al., 
2005). On the other hand, another study identified the same subset sitting at lymphatic 
sinuses on the medullary side of the LN, and they can capture large particulate antigens 
from lymph (Gerner et al., 2015). It is still unclear whether these are two separate subsets 
or the same migrating to different locations in the lymph node.  
Apart from its importance in mediating the migration of DCs from tissues towards the 
draining LN, CCR7 is also important for DCs to locate the TCZ (Ato et al., 2002; Braun et 
al., 2011). The TCZ of both LNs and the spleen are areas high in CCL19 and/or CCL21 
(Ato et al., 2002; Luther et al., 2000). and since cDC1s show higher expression of CCR7 
than cDC2s, they follow the CCL19 and CCL21 gradient and preferentially localize to the 
deep TCZ (Krishnaswamy et al., 2017). XCR1 selective expression by cDC1s potentially 
helps in establishing this niche since CD8+ T cells secrete its ligand XCL1 during early 
activation (Brewitz et al., 2017). 
On the other hand, cDC2s express higher levels of CXCR5 compared to CCR7 which 
causes them to be positioned at the T cell–B cell border after migration to the LN 
(Krishnaswamy et al., 2017). The chemotactic receptor Epstein–Barr virus induced gene 
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2 (EBI2) was recently shown to guide cDC2s to oxysterols at the T cell–B cell border in 
the spleen (Li et al., 2016) while cDC1s express enzymes that degrade oxysterols and 
therefore create a T cell area relatively devoid of EBI2 ligands (Lu et al., 2017). Also, 
selective expression of sphingosine-1-phosphate (S1P) receptor 3 (S1PR3) by cDC2s 
was observed and potentially results in sustained responsiveness to S1P gradients. S1P 
is concentrated in cortical sinusoids in the paracortex, which largely overlaps with the T 
cell–B cell border and the region with highest concentration of migratory cDC2s 
(Grigorova et al., 2010). 
 
 1.8 Dendritic cell control of T cell response 
(CD11c)-DTR mice showed that lack of CD11c+ cells led to the loss of CD8 T cell priming 
to cell-associated antigens and to intracellular pathogens such as Listeria 
monocytogenes and malaria (Jung et al., 2002). Later, Zbtb46-DTR mice lacking only 
cDCs resulted in a complete inability to prime CD8 or CD4 T cells against soluble antigen 
(Meredith et al., 2012) and a failure to prime CD4 T cells against Mtb (Samstein et al., 
2013). Additionally, cDC-specific deletion of MHCII expressing cells using Zbtb46-cre led 
to a complete reduction in CD4 T cell priming to soluble antigen (Loschko et al., 2016). 
Furthermore, antigen targeting to specific DC subsets indicated the functional 
specialization of each subset, with cDC1s preferentially priming CD8 T cells and the only 
subset efficiently carrying out cross-presentation of exogenous antigens on MHC class I, 
while cDC2s were more efficient in priming CD4 T cells (Dudziak et al., 2007). Depleting 
cDC1s using the Xcr1-DTRvenus strain also abrogated CD8 T cell priming against soluble 
and cell-associated antigen as well as against Listeria infection (Yamazaki et al., 2013). 
CD4 T cells could still be primed against soluble antigen in these mice. Future work with 
specific depletion of cDC2s is needed to confirm their unique role in priming CD4 T cells.  
  
1.8.1 Control of type 1 immune response 
Immune responses that are induced against intracellular pathogens and require IFN- 
activated macrophages and cytotoxic CD8 T cells for their clearance are termed type 1 
immune responses. In the early phases of the response, NK cells and innate lymphoid 
cells type 1 (ILC1s) are the major source of IFN- while antigen-specific Th1 and CD8 T 
cells produce this cytokine at later stages. The bioactive IL-12p70 is the major cytokine 
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required for activation of type 1 responses, as it drives NK cells and ILC1s to produce 
IFN-, and is responsible for polarizing naive T cells to type 1 helper (Th1) T cell 
(Macatonia et al., 1995). Over the years, many studies proved that cDC1s are the major 
non-redundant source of IL-12 and is responsible for mounting type 1 responses by T 
cells. Using the Karma mouse strain where cDC1s are specifically depleted completely 
abolishes IL-12 production in response to soluble Toxoplasma antigen and a significant 
reduction in IFN- levels (Alexandre et al., 2016). Also, Batf3-/- mice showed reduced IFN-
  production from NK cells during Toxoplasma infection, which indicates that IL-12 from 
cDC1s is critical for NK cell activation and reduced IFN- production (Askenase et al., 
2015). Additionally, using Itgax-DTR mice where all CD11c cells can be conditionally 
depleted (Neuenhahn et al., 2006), Batf3-/- mice (Edelson et al., 2011), Ly75-DTR 
(Fukaya et al., 2012), and Xcr1-DTRvenus (Yamazaki et al., 2013) mice where cDC1s 
are specifically depleted all showed reduced CD8 T cell responses in Listeria infection 
models. Interestingly, many of these models showed reduced Listeria burden in the 
spleen and in Batf3-/- mice increased resistance to the infection was even observed. This 
is because cDC1 infection by Listeria in the splenic marginal zone is important for them 
to spread and proliferate in the lymphoid areas of the spleen (Neuenhahn et al., 2006). 
Another role the cDC1s play in promoting the survival and activation of NK cells depend 
on their trans-presentation of IL-15. cDC1s express the non-signaling receptor chain IL-
15R and binds IL-15, then it presents it to the full IL-15αβ receptor on NK cells (Burkett 
et al., 2004; Mortier et al., 2008).  
Control of viral infections rely on CD8+ cytotoxic lymphocytes (CTLs), their activation 
requires the engagement of nucleic acid sensors by APCs leading to the production of 
type 1 interferons and IL-12. Both CD103+ DCs migratory as well as CD8α+ lymphoid-
resident DCs were shown to be capable of cross-presenting viral antigens and activating 
CD8+T cells (Waithman et al., 2013). Also, during a viral response, CD4 T cell help 
provided to CD8 T cells appears to be mediated through ‘‘licensing” of cDC1s. Analysis 
of immune responses suggests that CD4 T cells are primed by DCs earlier than CD8 T 
cells, this is followed by a three-way clustering of 1) CD4 T cells with; 2) cDC1s in order 
to license them, then with; 3) CD8 T cells which then get primed by the cDC1s that cross-
present the viral antigen to the CD8 T cells (Eickhoff et al., 2015; Hor et al., 2015). 
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1.8.2 Control of type 2 immune response 
Type 2 responses are mounted against multicellular parasites at barrier surfaces in order 
to aid in their expulsion. Several cytokines have been described that induce this response 
including IL-4 that polarizes naive T cells to Th2 cells(Le Gros et al., 1990), and IL-25 and 
IL-33 that activate innate lymphoid cells type 2 (ILC2s) and push them towards production 
of effector cytokines such as IL-4, IL-5, and IL-13 (Sonnenberg and Artis, 2015). Depletion 
of CD11c+ cells in Itgax-DTR mice abrogated type 2 responses to inhaled house dust mite 
(HDM) allergen (Hammad et al., 2010) and an FcεRI expressing CD11c+ MHCII+ cell 
population was shown to be the major subset responsible for the response. This was 
confirmed to be the cDC2 subset by a study which showed that conditional deletion of Irf4 
with Itgax-Cre (Gao et al., 2013) diminished Th2 priming in response to papain, which is 
a model allergen inducing Th2 response, and Nippostrongylus infection. Also, depletion 
of a subset of cDC2s, that depend on Klf4 for their development, using Klf4f/f Itgax-Cre 
strain increased susceptibility to Schistosoma mansoni infection and diminished allergic 
inflammation after intranasal HDM challenge (Tussiwand et al., 2015). The production of 
cytokines by DCs was not established in any of these models, so whether they control 
type 2 responses by this mechanism or some other is yet to be determined. Other studies 
suggested that ILC2s might be the source of cytokines acting to induce type 2 responses 
(Halim et al., 2014). It is possible that ILC2s and DCs cooperate in Th2 priming, though 
this is yet to be studied. Of note, in humans, Langerhans cells induce the secretion of Th2 
cell cytokines in mixed-leukocyte reactions more efficiently than other skin DC subsets 
do (Klechevsky et al., 2008; Segura et al., 2012). This suggests that different skin DC 
subsets can carry out the priming of Th2 cells in mice and humans depending on the 
context. 
1.8.3 Control of Th17 immune response 
Th17 immune responses is mainly carried out at barrier surfaces such as the lungs and 
intestines to control infections by extracellular bacteria and fungi. Cytokines including IL-
23 and IL-6, and TGF- are required for this response and IL-6, and TGF- initiate T 
helper 17 (Th17) cell polarization (Bettelli et al., 2006). On the other hand, IL-23 increases 
the survival and expansion of committed Th17 cells (Veldhoen et al., 2006). This cytokine 
is also critical for innate responses activating ILC3s to produce IL-22. This promotes 
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production of bactericidal lectins such as RegIII- from small intestinal epithelial cells 
(Kinnebrew et al., 2012; Sonnenberg and Artis, 2015). Citrobacter rodentium is a famous 
mouse pathogen used to study Th17 immune responses. It requires IL-23 and IL-22 for 
its clearance (Zheng et al., 2008); (Basu et al., 2012); (Mundy et al., 2005). Notch2-
dependent cDC2s were shown to be the critical source of IL-23 in defense against this 
pathogen (Satpathy et al., 2013) as demonstrated by conditional knockout of Notch2-
dependent cDC2s. Studies have also implicated cDC2s in various other Th17 immune 
responses. The depletion of CD103+ CD11b+ intestinal cDC2s, using Notch2f/f Itgax-cre, 
Irf4f/f Itgax-cre, or CD207-DTA mice, showed fewer small intestinal Th17 cells at steady 
state (Lewis et al., 2011); (Schlitzer et al., 2013a); (Welty et al., 2013). This was also the 
case for Th17 cells in the small intestine lamina propria and mesenteric LNs at steady 
state and less Th17 polarized cells after immunization with antigen plus CD40 and LPS 
(Persson et al., 2013). Another study also showed that cDC2s must produce IL-23 to 
activate IL-17 secretion from dermal -TCR T cells during cutaneous Candida albicans 
infection (Kashem et al., 2015). In conclusion, the depletion of cDC2s was clearly 
responsible for defects in Th17 responses to several pathogens, such as Citrobacter 
(Satpathy et al., 2013), Streptococcus (Linehan et al., 2015), and Candida (Kashem et 
al., 2015); (Trautwein-Weidner et al., 2015). On the other hand, Th17 responses were 
intact in mice lacking cDC1s which again underscores the functional specialization of 
different cDC subsets and the non-redundant roles they play in host defense.  
 
1.8.4 Interleukin-12 and its role in type 1 immune responses 
Interleukin 12 (IL-12) belongs to type I cytokines and has a four α-helical bundle structure. 
IL-12 acts in a form of a heterodimeric protein (IL-12-p70; IL-12-p35/p40) consisting of 
two covalently linked p35 and p40 subunits.  Following the discovery of IL-12, three other 
members (IL-23, IL-27, and IL-35) have been added to the IL-12 family and shown to play 
critical roles in Th1 cell functions. IL-12 is a ligand of a receptor composed of two amino 
acid chains, IL-12R-β1 and IL-12R-β2. IL-12 receptor (e.g., The IL-12R-β1 chain is 
expressed in a constitutive manner in B cells (Pistoia et al., 2009), while IL-12R-β2 is 
expressed in an inducible manner in a variety of immune cells, including NK cells, T, and 
B lymphocytes. Ligand-bound IL-12R-β2 becomes phosphorylated on tyrosines, which 
provides harboring sites for two kinases, JAK2 and TYK2. Among the STAT family of 
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transcription factors, STAT4 is considered the most specific mediator of cellular 
responses elicited by IL-12 (Thierfelder et al., 1996). In human T cells, both IFN-α and IL-
12 activate STAT4, yet IFN-α cannot substitute for the loss of IL-12 function in vivo, as 
judged by the fact that loss of IL-12R expression in humans results in a failure to induce 
protective Th1-mediated immune responses (Jong et al., 1998), (Altare et al., 1998). In 
addition to forming heterodimers with p35, both mouse and human p40 are secreted in 
large excess as free p40 monomers and can also form homodimers (p402), which exhibit 
biological activities antagonistic to heterodimeric IL-12p70 (Gillessen et al., 1995),(Ling 
et al., 1995). The production of immunosuppressive IL-12p40 homodimers was also 
induced in DCs and macrophages exposed to ultraviolet radiation (Schmitt and Ullrich, 
2000). Surprisingly, Jana et al. found that IL-12p70, p402 (the p40 homodimer) and p40 
(the p40 monomer) all induced the production of TNF-α in BV-2 microglial cells and in 
mouse primary microglia and peritoneal macrophages. 
IL-12p70 is released in response to intracellular bacterial and parasitic infections and 
though the relative roles of IL-12p70 and IFN- in Th1-cell priming is to a significant extent 
pathogen-dependent, in most infections IL-12p70 regulates the magnitude of the IFN- 
response at the initiation of infection, thus potentiating natural resistance, favoring Th1-
cell development, and inhibiting Th2 responses. Treatment of animals with IL-12p70, 
either alone or as a vaccine adjuvant, has been shown to prevent diseases caused by 
many of the same infectious agents, by stimulating innate resistance or promoting specific 
reactivity. 
Additionally, IL-12p70 plays a major role in tumor control and rejection (Eisenring et al., 
2010; Segal et al., 2002). Recombinant human IL-12p70 has been studied as a single 
agent for systemic treatment of various types of cancer in patients. A strong CTL response 
was observed in patients with advanced melanoma after IL-12p70 administration. The 
number of tumor-specific CTL increased in the circulation, and influx of specific memory 
CD8+ T cells into metastasized lesions was demonstrated (Lasek et al., 2014). 
 
 1.9 Bone marrow-derived dendritic cells 
Inaba and colleagues were the first to successfully generate large quantities of DC from 
mouse BM precursors supplied with GM-CSF (Inaba et al., 1992). About 5 × 106 DC at 
70% purity could be obtained per mouse after 6 days of culture. These monocyte-derived 
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cultured DC exhibited characteristic morphology and phenotype of DC, including the 
presence of small cytoplasmic protrusions and the expression of CD11c, high levels of 
MHC molecules and costimulatory molecules, and have a strong ability to initiate mixed 
leukocyte reaction (MLR). This method was further improved by our lab to generate higher 
yields and purities of DCs (Lutz et al., 1999). The major modifications include: the 
avoidance of any active depletion of BM cell subsets, reduction of GM-CSF concentration, 
a lower seeding density of BM cells and a prolonged culture period. With the modified 
method, a higher yield of 1–3×108 immature and mature DC per mouse at nearly 95% 
purity can be achieved (Lutz et al., 1999). Further maturation of DC could be induced by 
high doses of LPS or TNFα, where 50–70% of the non-adherent fraction represented 
mature DC expressing high levels of CD86 and CD40. Such matured BM-derived 
dendritic cells (BM-DCs) closely resemble the inflammation induced MoDCs (Inaba et al., 
1990; Lutz et al., 2017). 
Surprisingly, abrogation of GM-CSF or its receptor in mice did not affect MoDC generation 
and activation of CD8+ T cell responses. Conversely, deficiency of M-CSFR impaired 
inflammatory MoDC recruitment and CD80/CD86 surface expression (Greter et al., 2012). 
Thus, the role of GM-CSF in the generation of inflammatory MoDCs in vivo is yet to be 
determined.  
BM-DCs can also be generated using GM-CSF BM cultures supplemented with IL-4 both 
from mouse BM or peripheral blood monocytes (Schreurs et al., 1999), (León et al., 2004). 
Compared with DC differentiated in the presence of GM-CSF alone, additional 
supplementation of IL-4 significantly enhanced DC differentiation, leading to an 
intermediate degree of maturation (Labeur et al., 1999), and induced DC growth and 
maturation. IL-4 was also proposed to inhibit macrophage colony formation (Hiasa et al., 
2009).  
BM-DCs supplemented with IL-15 together with GM-CSF have similar phenotype and 
functions to that of GM-CSF/IL-4-induced DC (Pulendran et al., 2004). Notably, the 
cultured IL-15 DC displayed superior Th1 polarization and cytotoxic T lymphocyte (CTL) 
induction ability. They appear to also acquire cytotoxic capabilities upon LPS activation 
and exhibit direct tumoricidal function via expression of iNOS (Pulendran et al., 
2004);(Hanke et al., 2014).  
Unlike cDCs which show a specific and restricted functional profile; BM-DCs appear more 
versatile in their functions and have been shown to present and cross-present 
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equivalently well (Cheong et al., 2010). We and others have shown that they can be 
instructed by pathogens or inflammatory signals to induce Th1, Th2, and Th17 responses 
depending on the quality and magnitude of the stimulation. BM-DCs that were stimulated 
with TNF or Variant surface glycoprotein (VSG) from Trypanosoma induced an 
inflammatory response that correlates with Th2 polarizing capacity. This signature was 
changed significantly with a different quality and quantity of gene responses after LPS 
treatment of BM-DCs and they were shifted towards a Th1 inducing profile (Pletinckx et 
al., 2011). On the other hand, the use of high doses of cholera toxin induced a Th17-
polarizing BM-DC secreting Th17 characteristic cytokines such as IL-1β, IL-6 and IL-23 
(Silva-Vilches et al., 2017).  
 
1.10 Dendritic cell vaccination 
Due to the efficient protocols to generate large amounts of human MoDCs, the large body 
of evidences from studies using BM-DCs that show their strong anti-tumor activities in 
mouse models, and their possibility to direct both CD4 and CD8 T cell responses, they 
were the prime candidates for adoptive DC vaccine trials in tumor patients (Nestle et al., 
1998). Currently, peripheral blood mononuclear cells (PBMCs) are the most common 
source of cells for vaccine preparation (Reichardt et al., 2004). Since DCs circulate in 
peripheral blood with low frequency, they are usually differentiated from monocyte 
precursors that comprise up to 10% of PBMCs. PBMCs are usually obtained by 
leukapheresis and enriched for monocytes by their adherence to plastic and CD14 
selection. Differentiation of monocytes into immature DCs is then achieved by culture with 
cytokines, most often granulocyte/macrophage colony stimulating factor (GM-CSF) and 
IL-4. Alternative cytokine cocktails, including GM-CSF/IL-15 (Anguille et al., 2009) and 
IFN-β/IL-3 (Trakatelli et al., 2006), have also been used to optimize vaccine preparation, 
although these are not as well studied in the clinic. DC maturation is typically achieved by 
a standard cytokine consisting of GM-CSF, IL-4, IL-1β, IL-6, TNF-α and prostaglandin 
(PGE)-2 (Jonuleit et al., 1997), or from Toll-like receptor (TLR) ligands such as dsRNA or 
CpG motifs. Several dosing forms have been used in clinical trials including intradermal, 
intramuscular, intravenous or intratumoral. (Anguille et al., 2009; Jonuleit et al., 1997; 
Reichardt et al., 2004; Ridgway, 2003; Trakatelli et al., 2006). The most characteristic 
feature of DC vaccination is their very high tolerability by most of the patients and a low 
toxicity profile (Mitchell et al., 2015b),(Krishnadas et al., 2015). However, the clinical 
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picture so far of most DC vaccine clinical trial do not show a very high response rate. Only 
one vaccine DC has gained an FDA approval so far which is Sipuleucel-T, and it has 
shown sufficient efficacy in a Phase III clinical trials (Kantoff et al., 2010). The 
immunosuppressive milieu of tumors is one of the major contributing factors to the low 
responsiveness to DC vaccination and many studies try to combine DC vaccines with 
agents that counter the immunosuppression. This included PD-L1 combination, which 
showed high IL-12 production capacity by DCs and better T cell responses. Also, a 
reduction in tumor size was observed in a breast cancer model (Ge et al., 2013). Other 
studies combined DC vaccines with IL-10 blocking antibodies, which shows better NK 
responses, increased tumor shrinkage, and increased survival in a murine breast cancer 
model (Rossowska et al., 2015). Another strategy that was used is the repeated injection 
of DCs or pre-injection of the DC injection site with TNF. This was shown to dramatically 
enhance the migration of injected DCs (MartIn-Fontecha et al., 2003). Also, pretreatment 
of the injection site with tetanus/diphtheria toxoid was shown to dramatically improve the 
vaccine efficacy (Mitchell et al., 2015a). The use of low doses of GM-CSF was also shown 
to be beneficial (Parmiani et al., 2007).  
 
1.11 In vitro GM-CSF DCs as a source of IL-12 
The introduction so far shows that the induction of Th1 responses by DCs relies on three 
distinct stimuli coming from DCs. The combination of signal 1 by MHC peptide complexes 
ligating the TCR with signal 2 by CD80/CD86 co-stimulation will lead to T cell activation 
and proliferation, reaching the Th0 stage, previously observed in mouse T cell clones, 
(Openshaw et al., 1995). A major signal 3 for the induction of Th1 responses has been 
identified as the heterodimeric IL-12p70 cytokine (Fig 2) (Macatonia et al., 1995). IL-12 
production by DCs can be induced by different pathogen signals but not pro-inflammatory 
cytokines (Reis e Sousa et al., 1997). 
 
26 
 
 
 
Figure 2: The three-signal theory of T cell priming by DCs. A single DC primes the naive T cell towards Th1 cell type by providing 3 
signals: 1) Peptide presented on MHC II, 2) Co-stimulation by the CD80/CD86 molecules, 3) IL-12p70 required for Th1 polarization 
 
Surprisingly, in the DC vaccination setup, several findings question the common believe 
that injected vaccine MoDCs do provide all signals 1, 2 and 3 for Th1 priming, which is 
the classical model of DC priming of T cells (Kapsenberg, 2003). 
Several DC vaccination studies in tumor patients use the cytokine cocktail consisting of 
IL-1/TNF/IL-6/PGE2 (Jonuleit et al., 1997) for maturation of MoDCs, (Bol et al., 2016); 
(Gross et al., 2017). Although tumor therapy with this cocktail matured MoDCs has proven 
to be successful in melanoma patients and is in fact the most common used approach, 
MoDCs generated with this cocktail unexpectedly are unable to produce IL-12 (Lee et al., 
2002). Despite readily being able to induce Th1 responses in these patients (Gross et al., 
2017); this cocktail was compared to synthetic double stranded RNA (poly I:C), soluble 
CD40 ligand trimer as maturation cues. And while all maturation stimuli induce a mature 
dendritic cell phenotype, the IL-1/TNF/IL-6/PGE2 cocktail was the most efficient despite 
the lack of induction of IL-12p70.  
In another study that used BM-DCs from IL-12-deficient mice for vaccination against 
Leishmania major infection indicated that the development of Th1 responses relied on an 
undetermined source of IL-12 production by the recipient mice, not the injected DCs 
(Ramirez-Pineda et al., 2004), The immunization of mice with a single dose of BM-DCs 
that were pulsed with Leishmania major Ag and activated with CpG ex vivo was enough 
to confer a very high level of protection against a normally lethal challenge with L. major. 
Unexpectedly though, the level of IL-12 released by BM-DCs did not correlate with their 
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capacity to mediate protection against leishmaniasis, since they did not express high 
amounts of IL-12. The LmAg-induced reduction of the IL-12 production by CpG-activated 
BM-DCs was a consistent finding.  This was supported by the finding that the protective 
efficacy of Ag-loaded BM-DCs from Il12a-/- or Il12b-/- mice was virtually identical with that 
of BM-DCs obtained from WT mice, excluding also a role of the related cytokine IL-23, 
which shares the p40 subunit with IL-12. Rather, IL-12-deficient mice with CpG-activated 
BMDC delivering LmAg did not result in protection, demonstrating that IL-12 released by 
recipient cells is required. Interestingly, the same group previously showed that when Ag-
pulsed Langerhans cells from IL-12-deficient mice were as the source of DC, they 
completely failed to mediate protection against L. major as opposed to those from WT 
mice (Berberich et al., 2003). This underscores the importance of the type of DC used for 
vaccination approaches.  
Additionally, previous data from our group showed that injected BM-DCs reaching the 
draining lymph node lack IL-12 production among other cytokines, and they rather induce 
cytokine production by host endogenous DCs. LPS + CD40-matured BM-DCs that were 
secondarily matured with TNF in vitro activated their cytokine production. However, upon 
reaching the lymph nodes they were negative for intracellular TNF, IL-6, IL-12p40, IL-10 
cytokines (Voigtlander et al., 2006). On the other hand, endogenous DC population 
stained positive for all these cytokines with higher levels for TNF, IL-6, and IL-12p40 after 
LPS + CD40-matured BM-DC injection as compared with TNF-matured BM-DC injection. 
In this study GM-CSF without IL-4 was used for differentiating the BM-DCs. IL-4 in these 
GM-CSF cultures promotes the Langerhans cell-like phenotype (Menges et al., 2005). 
And since no IL-4 was used in the GM-CSF cultures here, this data is in agreement with 
the reports from the Leishmania major model (Berberich et al., 2003; Ramirez-Pineda et 
al., 2004). Such a model of BM-DCs being incapable of cytokine production upon 
migrating to the lymph nodes and rather induce cytokine production from other DCs is in 
agreement with data from Luft and colleagues (Luft et al., 2004), that showed that CCR7 
dependent migration of MoDCs and their ability to produce IL-12 are mutually exclusive 
events. 
 
1.12 DC-DC cross talk for propagation of the immune response 
Emerging evidences from the literature indicated that dendritic cells from different subsets 
communicated with each other and one DC can possibly induce the activation of another 
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DC in a bystander fashion under certain pathological conditions (Brewitz et al., 2017; De 
Koker et al., 2017; Plantinga et al., 2013). One study showed that communication of pDCs 
with XCR1+ cDC1s is required to induce optimal CTL responses in a vaccinia virus setup 
(Brewitz et al., 2017). Also, the production of IL-12 by MoDCs under CpG vaccination 
conditions required the coordinated action of cDCs and MoDCs (De Koker et al., 2017). 
Also in a house dust allergy model, it was shown that MoDCs were mainly responsible 
for proinflammatory cytokine production in the lungs while CD11b+ migratory cDC2s were 
responsible for antigen presentation and inducing Th2 responses in the LN, suggesting 
the requirement of their concerted actions (Plantinga et al., 2013). 
The possibility of BM-DCs communicating with other endogenous DCs in the draining 
lymph nodes is suggested by the studies described in the previous section. However, 
there are no concrete evidences for which endogenous DC subset is being activated by 
BM-DCs in a bystander fashion and carry out the IL-12 production and Th1 priming 
function. Nothing is also known about the possible molecular patterns involved in this 
presumed crosstalk. 
One possible mechanism for this communication between DCs is via the interaction of 
the tumor necrosis factor receptor family member 9 (TNFRSF9 or 4-1BB) with its ligand 
TNFSF9 or 4-1BBL. 4-1BB was first thought to only be an important mediator of survival 
signaling, particularly in CD8+ T cells. Later however it was shown that they are more 
broadly expressed on regulatory T cells (Tregs) (Gavin et al., 2002), (McHugh et al., 
2002), follicular dendritic cells (DCs) (Pauly et al., 2002), DCs (Futagawa et al., 2002), 
(Wilcox et al., 2002a), differentiating myeloid‐lineage cells (Lee et al., 2008), monocytes 
((Langstein et al., 1998), immunoglobulin E (IgE)‐stimulated mast cells (Nishimoto et al., 
2005), eosinophils (Heinisch et al., 2001), neutrophils (Heinisch et al., 2000), (Lee et al., 
2005)), activated natural killer T cells (NKTs) (Vinay et al., 2004), and activated NK cells 
(Melero et al., 1998), (Wilcox et al., 2002b). 4‐1BBL is strictly induced on activated APCs 
(Futagawa et al., 2002), (Goodwin et al., 1993) and is also expressed on myeloid 
progenitors and hematopoietic stem cells (Lee et al., 2008), (Jiang et al., 2008a), (Jiang 
et al., 2008b). Its expression appears to be tightly regulated in vivo, such that its 
expression during an ongoing immune response in vivo is difficult to detect at the protein 
level (Lin et al., 2009). However, during chronic and inflammatory conditions 4‐1BBL is 
more readily detectable at the mRNA or protein level (Tan et al., 2000), (Lin et al., 2009), 
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(Seko et al., 2001), (Mack et al., 2008). On macrophages, 4‐1BBL message is induced 
by LPS in a Toll‐like receptor 4 (TLR4), nuclear factor kappaB (NF‐κB)‐dependent manner 
(Futagawa et al., 2002), (Goodwin et al., 1993), (Kang et al., 2007). Its expression is rapid 
and transient, with peak mRNA expression on macrophages at 4h and returning to 
baseline by 12h (Kang et al., 2007)). 4‐1BBL is also upregulated on B cells and DCs by 
CD40 signaling (DeBenedette et al., 1997), (Diehl et al., 2002). The interaction of 4-1BBL 
on mature DC with 4-1BB on co-cultured immature DCs has been shown to induce IL-12 
production by the immature DCs (Futagawa et al., 2002). Additionally, a more recent 
study showed that upon injecting lentiviral vectors (LV) expressing 4-1BBL and influenza 
nucleoprotein (NP) separately; they conferred superior CD8 T cell activation capacity than 
LV co-expressing 4-1BBL and NP, i.e. to target CD8 T cells that recognize the influenza 
antigen and receive further activation signals from the 4-1BBL. This suggested that 4-
1BBL is more effective when expressed in trans, acting on adjacent DCs and thus 
activating them in a bystander fashion (Macdonald et al., 2014).  
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1.13 Aim of the study 
In this study we aimed to clarify the cellular sources of IL-12p70 production after 
subcutaneous BM-DC vaccine injection in the skin draining lymph node, and to study the 
possibility of bystander activation of different endogenous DC subsets upon interacting 
with the injected BM-DCs. We generated a chimeric situation by injection of different 
gene-modified BM-DCs into different strains of gene-modified recipient mice. This allowed 
us to identify the separate functional contributions of injected versus endogenous DCs for 
Th1 polarization.  
 
The study attempts to answer 3 main questions:  
1- Which DC subset is the source of IL-12p70 needed for Th1 induction during BM-DC 
vaccination? 
2- Are BM-DCs communicating with endogenous DCs to induce bystander DCs in the 
draining lymph nodes? 
3- If so, how and when are they communicating and what signals are communicated to 
the bystander DCs? 
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2 MATERIALS AND METHODS 
2.1 Reagents 
2.1.1   Chemical reagents 
Product                                      Purchased from 
 
Agarose Roth (Karlsruhe, Germany) 
Ammonium Chloride (10% solution) Applichem (Darmstadt, Germany) 
β-mercaptoethanol Sigma-Aldrich (Deisenhofen, Germany) 
Brefeldin A (from Penicillium 
brefeldianu) 
Sigma-Aldrich (Deisenhofen, Germany) 
BSA Roth (Karlsruhe, Germany) 
Complete Freund’s Adjuvant (CFA) Sigma-Aldrich (Deisenhofen, Germany) 
CellTrace™ Violet Cell Proliferation 
Dye 
Invitrogen (Darmstadt, Germany) 
CFSE (carboxyfluorescein diacetate 
succinimidyl ester) 
Invitrogen (Darmstadt, Germany) 
Chloroform Applichem (Darmstadt, Germany) 
Complete Freund’s Adjuvant (CFA) Sigma-Aldrich (Deisenhofen, Germany) 
CpG ODN Sigma-Aldrich (Deisenhofen, Germany) 
DEPC (diethyl pyrocarbonate) Roth (Karlsruhe, Germany) 
DMSO (dimethyl sulfoxide) Sigma-Aldrich (Deisenhofen, Germany) 
Diphtheria Toxin Sigma-Aldrich (Deisenhofen, Germany) 
dNTPs Fermentas (St. Leon-Rot, Germany) 
EDTA Applichem (Darmstadt, Germany) 
eFluor™ 670 Cell Proliferation Dye Invitrogen (Darmstadt, Germany) 
Ethanol Applichem (Darmstadt, Germany) 
Ethidium Bromide Roth (Karlsruhe, Germany) 
Fetal Calf Serum (FCS) PAA Laboratories (Pasching, 
Austria)   
Fluoromount-G Serva Electrophoresis (Germany) 
Formaldehyde (37%) Roth (Karlsruhe, Germany) 
Hydrogen Peroxide (30%) Applichem (Darmstadt, Germany) 
IC Fixation buffer Affymetrix eBioscience 
Ionomycin calcium salt (from 
Streptomyces) 
Sigma-Aldrich (Deisenhofen, Germany) 
Isopropanol Applichem (Darmstadt, Germany) 
L-Glutamine PAA Laboratories (Pasching, Austria) 
L-Lysine Sigma-Aldrich (Deisenhofen, Germany) 
LPS (E. coli 0127:B8) 
Sigma-Aldrich (Deisenhofen, Germany) 
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Methanol 
Applichem (Darmstadt, Germany) 
Paraformaldehyde 
Sigma-Aldrich (Deisenhofen, Germany) 
Penicillin/Streptomycin PAA Laboratories (Pasching, Austria) 
PMA (Phorbol 12-myristate 13-acetate) Sigma-Aldrich (Deisenhofen, Germany) 
Sodium azide (NaN3) Roth (Karlsruhe, Germany) 
Sodium (meta)periodate Sigma-Aldrich (Deisenhofen, Germany) 
Sodium phosphate dibasic Sigma-Aldrich (Deisenhofen, Germany) 
Sodium phosphate monobasic Sigma-Aldrich (Deisenhofen, Germany) 
Sucrose ≥99.5% Sigma-Aldrich (Deisenhofen, Germany) 
TRIzol (Darmstadt, Germany) Sigma-Aldrich 
Tris Applichem 
Tissue-tek  Sakura 
Triton X-100 Sigma-Aldrich (Deisenhofen, Germany) 
Trypan blue Sigma-Aldrich (Deisenhofen, Germany) 
Table 1. List of chemical reagents used throughout experimental set-up 
 
2.1.2   Primary Antibodies 
  2.1.2.1 Primary antibodies directed against surface or intracellular markers 
Antigen Clone Dilution Fluorochrome Purchased from 
CD4 GK 1.5 1:150 APC Biolegend 
CD4 GK 1.5 1:150 FITC Biolegend 
CD8 53-6.7 1:150 Pacific Blue Biolegend 
CD11b M1/70 1:300 PerCP-Cy5.5 Biolegend 
CD11c N418 1:100 APC Biolegend 
CD11c N418 1:100 PE-Cy7 Biolegend 
CD27 LG3A10 1:100 Pacific Blue Biolegend 
CD45R (B220) RA3-6B2 1:200 APC Biolegend 
CD64 X54-5/7.1 1:100 PE Biolegend 
CD70 FR70 1:100 PE Biolegend 
CD90.1 (Thy1.1) OX-7 1:150 PerCP-Cy5.5 Biolegend 
CD90.1 (Thy1.1) HIS51 1:500 biotinylated BD biosciences 
CD103 2E7 1:100 PerCP-Cy5.5 Biolegend 
CD103 2E7 1:100 biotinylated Biolegend 
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CD137 (4-1BB) 17B5 1::100 PE BD biosciences 
CD137L (4-1BBL) TKS-1 1:100 PE BD biosciences 
F4/80 BM8 1:100 FITC Biolegend 
I-A/I-E (MHC II) M5A/114.15.2 1:600 Alexa Fluor 700 Biolegend 
Ly-6C HK1.4 1:200 Brilliant Violet 
510™ 
Biolegend 
XCR1 ZET 1:100 APC Biolegend 
   Table 2. List of antibodies directed against surface markers, intracellular markers or transcription factors 
  2.1.2.2 Primary antibodies directed against cytokines 
Antigen Clone Dilution Fluorochrome Purchased from 
IFN- XMG1.2 1:100 PE Biolegend 
IL-2 JES6-5H4 1:200 PE Biolegend 
IL-12p35 4D10p35 1:100 PE eBioscience 
IL-12p40 C11.5 1:00 PE BD biosciences 
IL-12p70 R2-9A5 1:100 unconjugated Bio X Cell 
IL-13 85BRD 1:300 PE BD biosciences 
     Table 3. List of antibodies directed against cytokines 
  
  2.1.2.3 Secondary antibodies or conjugates 
      
Antigen Host Dilution Fluorochrome Purchased from 
anti-rat IgG,  light 
chain 
Goat 1:200 PE BD biosciences 
Streptavidin  x 1:500 PE-Cy7 Biolegend 
Streptavidin x 1:300 Brilliant Violet 
510™ 
Biolegend 
Streptavidin x 1:500 Cy3 Biolegend 
     Table 4. List of secondary antibodies or conjugates 
 
2.2 Buffers, media and solutions 
For preparation of buffers and solutions, ultrapure Milli-Q water was obtained from Milli-
Q water purification systems (Millipore, Schwalbach/Ts, Germany) 
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Buffers Composition 
PBS (phosphate buffered saline) 
0.2g KCl 
8.0 g NaCl 
KH2PO4 1.15 g 
1.15 g Na2HPO4 
Fill up to 1l Milli-Q water 
RPMI 1640 complete medium 
500ml RPMI 1640 (PAA 
Paching Austria) 
10% heat-inactivated 
sterile filtered FCS(PAA) 
100U/ml penicillin(PAA) 
100μg/ml streptomycin 
(PAA) 
2mM L-glutamine (PAA) 
50mM -mercaptoethanol (Sigma-Aldrich) 
DC preparation buffer 
45ml PBS 
5ml FCS 
100μg EDTA (0.5 M) 
FACS buffer 
500ml PBS 
0.1% BSA (Roth) 
0.1% NaN3 (Roth) 
Fixation buffer (2% FA) 
35ml PBS 
2ml Formaldehyde (37%) (Roth) 
Perm buffer 
PBS  
0.1% BSA (Roth) 
0.1% NaN3 (Roth) 
0.5% Saponin (Sigma-Aldrich) 
HL1 complete medium 
500ml HL1 (Lonza, Verviers Belgium) 
100U/ml penicillin (PAA) 
100µg/ml streptomycin (PAA) 
2mM L-glutamine (PAA) 
50mM-mercaptoethanol (Sigma-Aldrich) 
MACS Buffer 
PBS 
0.5% FCS (PAA) 
2mM EDTA (Applichem) 
PLP fixation buffer 
1% paraformaldehyde  
0.075M L-Lysin 
0.01M Sodium (meta)periodate 
Di-basic buffer 
7.098g Sodium phosphate dibasic 
50ml ddH2O 
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Mono-basic buffer 
6g Sodium phosphate dibasic 
50ml ddH2O 
Phosphate buffer 
75% Di-basic buffer 
25% Mono-basic buffer 
Tris-acetate-EDTA 
242g Tris 
57.1ml Acetic acid 
100ml (0.5M) EDTA 
Fill up to 1l DEPC-treated water 
       Table 5. List of secondary antibodies or conjugates 
 
2.3 Mice 
C57BL/6 were purchased from Charles River (Sulzfeld, Germany) and bred in house, OT-
II mice were kindly provided by Francis Carbone, Melbourne, Australia and were crossed 
with congenic C57BL/6 Thy1.1 mice. Il12a-/- (Mattner et al., 1996) and Yet40 reporter 
mice (Reinhardt et al., 2006) were kindly provided by Gottfried Alber. Ccr7-/- mice (Forster 
et al., 1999) were obtained from Martin Lipp and Reinhold Förster. Yet40.Ccr7-/- and 
Il12a.Ccr7-/- mice were bred in house. Xcr1-DTR-venus mice (Yamazaki et al., 2013) were 
kindly provided by Wolfgang Kastenmüller, and MHCII-/- mice (Madsen et al., 1999) were 
provided by Andreas Beilhack. All genetically-modified mice were on a C57BL/6 
background. All mice were bred in our own animal facilities at Würzburg, kept under 
specific pathogen-free conditions, and used at an age of 6 to 12 weeks. All animal 
experiments were performed according to the German animal protection law as well as 
after approval and under control of the local authorities. 
 
2.4 Primary cell techniques  
2.4.1 Handling of cells  
All procedures were performed under sterile conditions in class II biological safety 
cabinets (Thermo Scientific, Langenselbold, Germany) and using sterile plastic and glass 
ware. Cells were incubated in an incubator set at 37°C with 7 % CO2 atmosphere. Before 
use, culture medium was prewarmed to 37°C in a water bath. Centrifugation was 
performed at 1200 rpm for 5 minutes at RT unless indicated. 
2.4.2 Counting cells  
To determine cell concentration, 5 to 10 µl of a cell suspension was diluted in a trypan 
blue solution (Sigma-Aldrich, Deisenhofen, Germany) for visualization of non-viable cells 
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and counted by using a Neubauer counting chamber (Hartenstein, Wuerzburg, Germany) 
and an Axiostar plus microscope (with A-Plan objective 10x/0.25 Ph1, Carl Zeiss 
MicroImaging, Goettingen, Germany). Cell concentration was determined using the 
following formula: [(number live cells large quadrant 1 + number live cells opposing large 
quadrant 2) / 2] *dilution *104 = cells/ml 
2.4.3 Generation of GM‐CSF cell supernatant  
Culture supernatant for BM-DC generation was obtained from a murine GM-CSF 
transfected X63-Ag8.653 myeloma cell line kindly provided by B. Stockinger (London, 
UK). The GM-CSF transfected cell line was thawed according to standard procedure and 
left for 2 days in a T75 cell culture flask (Greiner Bio-One, Frickenhausen, Germany). 
Then, 107 cells were harvested and transferred to a T182 cell culture flask (Greiner Bio-
One) in ca. 90ml complete RPMI 1640 (PAA, Pasching, Austria). After 3-4 days, cell line 
reached cell growth confluence of ca. 90% in T182 cell culture flask after which culture 
supernatant was harvested and centrifuged at 1000rpm for 10 minutes. Harvested culture 
supernatant was sterile-filtered and frozen at -20°C until usage in generation of BM-DCs. 
2.4.4 Isolation of bone marrow (BM) cells  
BM-DC were generated as previously described (Lutz et al., 1999). Briefly, hind limbs 
were removed from 6 to 12-week-old mice and bones were relieved from surrounding 
muscle tissue by rubbing with unsterile paper tissues. Then, intact bones were soaked 
for 1-2min in sterile 10cm petri dishes (#664102, Greiner Bio-One, Frickenhausen, 
Germany) filled with an ethanol-propanol solution (Terralin® liquid, Schülke & Mayr, 
Norderstedt, Germany) for disinfection. Remaining alcohol was evaporated by air. A 
minimal fraction of both ends of the tibiae or femurs was cut by scissors and bone marrow 
was flushed out with a PBS-filled sterile 10ml tuberculin syringe (Pentaferte, Campli, Italy) 
using a Neoject® 27G or 0.40mm diameter needle (Dispomed Witt, Gelnhausen, 
Germany). Bone marrow was washed once by centrifugation at 1000rpm for 10 minutes 
and clusters of the BM cell suspension was disrupted by vigorous pipetting. About 5 to 7 
x 107 BM cells could be obtained from one mouse. 
2.4.5 Generation of GM‐CSF derived BM‐DCs   
At day 0, BM cells were seeded at 3 x 106 in sterile 10cm petri dishes (#664102, Greiner 
Bio-One, Frickenhausen, Germany) containing 10 ml complete RPMI 1640 medium 
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supplemented with 10% culture supernatant from a murine GM-CSF transfected X63-
Ag8.653 myeloma cell line. At day 3, another 10 ml complete RPMI 1640 medium 
containing 10% GM-CSF culture supernatant was added to the plates. At day 6, BM cells 
were fed by gently removing 10ml old RPMI 1640 medium and adding 10ml fresh 
complete RPMI 1640 medium containing 10% GM-CSF culture supernatant. The non-
attached cells were harvested and used at day 8. Procedure typically yields 60-80% 
CD11chigh expressing cells as determined by flow cytometry. 
2.4.6 Generation of single cell suspension from spleen and lymph nodes  
Skin-draining lymph nodes (popliteal, inguinal, and cervical) and spleens were isolated 
from 6-12-week-old mice under sterile conditions and transferred in 5cm petri dishes 
(Greiner Bio-One, Frickenhausen, Germany) containing ice-cold sterile PBS. Organs 
were cut into small pieces using forceps and digested for 20 min at RT with 1 mg/ml 
DNase I (Roche) and 1 mg/ml collagenase IV (Worthington) in DC preparation buffer. A 
single cell suspension was obtained by mashing spleen/ Lymph nodes with tuberculin 
syringe. Then, cell suspension was filtered through a 0.70μm nylon cell strainer (BD 
Biosciences, Heidelberg, Germany) positioned on a 5cm petri plate. Cells were then 
washed by centrifugation at 1000rpm for 5 minutes at 25°C. For spleen cell suspension, 
an erythrocyte lysis was performed by resuspending cell pellet in a 1:1 solution of PBS 
and 1.67% ammonium chloride (NH4Cl) buffer followed by incubation for 3 minutes in 
37°C pre-warmed water bath. To remove ammonium chloride, splenocytes were washed 
by centrifugation at 1000rpm for 5 minutes at 1200rpm at 4°C prior to determination of 
cell count number as described in previous section.  
2.5 Standard immunological/molecular techniques 
2.5.1 Flow cytometry 
2.5.1.1 Surface staining  
Cells were stained in FACS buffer containing ice-cold PBS supplemented with 0.1% BSA 
and 0.1% sodium azide. To avoid unspecific antibody binding, cells were incubated with 
supernatant derived from the 2.4G2 hybridoma cell line (anti-Fc-gamma-RII/III; ATCC, 
Wesel, Germany). Typically, 5 x 105
 
to 106 cells were stained in 50μl FACS buffer 
supplemented with antibodies directed against surface markers in a particular dilution 
(see table) for 20-30 minutes at 4°C in the dark. To remove unbound antibodies, cells 
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were washed by centrifugation at 1200rpm for 5 minutes at 4°C. Samples were stored in 
100μl of a 1:1 solution containing 1 part FACS buffer and 1 part 2% Formaldehyde until 
samples were acquired at a FACS LSR II flow cytometer (BD Biosciences, Heidelberg, 
Germany) provided with BD FACSDIVA™ Software (BD Biosciences) and data were 
analyzed with FlowJo software (TreeStar, Ashland, USA).  
2.5.1.2 Intracellular cytokine staining  
For intracellular cytokine detection, cells were stained for surface markers as described 
prior to fixation in a 2% formaldehyde solution during 20-30 minutes at 4°C in the dark. 
Then, cells were washed with FACS buffer by centrifugation on 1200rpm for 5 minutes at 
4°C followed by permeabilization in Perm Buffer for 30 minutes at 4°C in the dark. Staining 
of intracellular cytokines was performed using antibodies diluted in 50 μl Perm buffer for 
30 minutes at 4°C in the dark followed by washing with Perm buffer to remove unbound 
antibodies and analysis on flow cytometer.  
2.5.2 BM-DC labelling 
Day 8 BM-DCs were labeled with either CFSE for in vitro studies, eFluor™ 670 Cell 
Proliferation Dye for injection into YET40 mice, or with CellTrace™ Violet Cell 
Proliferation Dye for other in vivo experiments. For CFSE labelling, cells were labelled by 
adjusting to 2*107 cells/ml in PBS followed by CFSE addition in a final concentration of 
3µM. Cells were labelled at room temperature for 10 min in a light-protected environment 
followed by extensive washing. For eFluor™ 670 labelling, cells were resuspended at 107 
cells/ml and were resuspended in 10 ml PBS + 3.5 l of eFluor™ 670. Cells were 
incubated in the dark for 15 minutes, 3 ml of complete RPMI 1640 (PAA, Pasching, 
Austria) was added to stop the reaction. Cells were then centrifuged at 1000rpm for 10 
minutes and the cell pellet, which was blue indicative of successful staining, was 
resuspended in PBS at 4* 107 cells/ml to be injected. For CTV labelling, cells were 
pelleted and resuspend at 1*107 cells/ml in CTV stain solution (CTV 1:1000 in PBS). Cells 
were incubated for 6 minutes at room temperature, followed by adding 0.5 ml of FCS and 
10 ml of complete RPMI 1640 (PAA, Pasching, Austria). Cells were incubated again in a 
water bath prewarmed to 37°C. Cells were then centrifuged at 1000rpm for 10 minutes 
and the cell pellet, which was blue indicative of successful staining, was resuspended in 
PBS at 4* 107 cells/ml to be injected. 
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2.6 Specialized immunological techniques  
2.6.1 BM-DC maturation  
For in vitro experiments, BM-DCs were harvested at day 8 and re-plated at a density of 
106 cells per ml in a 24-well plate (non-tissue culture treated; Greiner Bio-One, 
Frickenhausen, Germany). For maturation analysis by surface marker expression or 
cytokine production, BM-DC were cultured for 20-24 hours (unless otherwise indicated) 
in the presence of 0.5 µg/ml LPS (Sigma-Aldrich, Deisenhofen, Germany) or 5 nmol/ml 
CpG (Sigma-Aldrich, Deisenhofen, Germany). As a control cells were left untreated for 
the same period. For s.c. injections BM-DCs were harvested at day 8 and centrifuged at 
at 1000rpm for 10 minutes and the cell pellet was resuspended in the same 50 ml Falcon 
tube (Greiner Bio-One, Frickenhausen, Germany) in 5 ml of complete RPMI 1640 (PAA, 
Pasching, Austria) and 0.5 µg/ml LPS (Sigma-Aldrich, Deisenhofen, Germany) or 5 
nmol/ml CpG (Sigma-Aldrich, Deisenhofen, Germany) were added. In case of additional 
injection of OT-II Thy1.1+ cells, the BM-DCs were incubated with OVA-peptide327-339 in 
addition to LPS or CpG. Cells were incubated at 37°C for 4 hours and were placed in a 
tilted position and shaken every 1 hour to prevent their attachment to the plastic. 45 ml of 
PBS were added to the cells and they were centrifuged at at 1000rpm for 10 minutes. 
This process was repeated twice to remove any remaining attached LPS. Cells were then 
labelled as described in the previous section. 
2.6.2 BM-DC vaccination 
LPS or CpG matured BM-DCs were injected into the footpad or into the flanks of mice. 
Popliteal or Inguinal lymph nodes were collected at the given time points, respectively. In 
case of adoptive OT-II.Thy1.1+ T cell transfer, single cell suspensions of lymph nodes 
(pooled skin-draining and mesenteric lymph nodes) and spleens from OT-II.Thy1.1+ mice 
were prepared as described above. Cells were labeled with CellTrace™ Violet Cell 
Proliferation dye (Sigma-Aldrich, Deisenhofen, Germany) and 1x107 cells were injected 
into the lateral tail vein of recipient mice. The cells were allowed to circulate in the mice 
for one day. On the next day, the OVA-peptide327-339 loaded, LPS or CpG matured BM-
DCs were injected into the footpad or into the flanks of mice, 2x106 cells were injected on 
each side. Popliteal or Inguinal lymph nodes were collected at the given time points, 
respectively. 
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2.6.3 Yet40 immunization by Complete Freund’s adjuvant  
Yet40 mice were injected s.c. on both flanks with 100µg of Complete Freund’s adjuvant 
(CFA; Sigma-Aldrich, Deisenhofen, Germany) further enriched with 5mg/ml 
Mycobacterium tuberculosis H37RA (Difco Laboratories, Detroit, USA) by using 
Sterican® 23G or 0.60mm diameter needles (Braun, Melsungen, Germany) and a 1ml 
Injekt®-F syringe (Braun). Inguinal, cervical lymph nodes, and spleens were collected 
24h after the injection and analyzed by flow cytometry. 
2.6.4 Ex vivo stimulation and cytokine staining of cells from lymph nodes and 
spleen 
Single cell suspensions from skin-draining lymph nodes or from spleen were prepared as 
described above and resuspended at a density of 2x106 cells per ml in HL1 complete 
medium (Lonza, Verviers Belgium), this medium does not contain FCS to avoid unspecific 
T cell reactivation. Intracellular cytokine detection was performed by restimulation with 
0.01µg/ml PMA (Sigma-Aldrich, Deisenhofen, Germany) and 1µg/ml ionomycin calcium 
salt (Sigma-Aldrich) in the presence of 5µg/ml Brefeldin A (from Penicillium brefeldianu, 
Sigma-Aldrich) followed by standard intracellular staining procedures as described in flow 
cytometry section.  
 2.6.5 Depletion of XCR1+ DCs in Xcr1-DTR-venus mice 
Xcr1-DTR-venus mice have a human diphtheria toxin (DT) receptor (DTR) transduced 
into the Xcr1 gene locus, followed by a fluorescent protein, venus, under the control of 
the Xcr1 gene promoter (Yamazaki et al., 2013). Upon injecting DT, targeted deletion of 
Xcr1 expressing cells is achieved. In our experimental setup, transgenic mice were 
treated with 0.5 µg diphtheria toxin (DT) i.p. (Sigma-Aldrich, Deisenhofen, Germany) on 
the same day when OT-II.Thy1.1+ cells were injected i.v. (day -1). On the following day 
the same dose was injected together with 106 of OVA-peptide327-339 loaded, LPS matured 
BM-DCs (day 0). On day 3 and day 5 0.25 µg of DT was injected. Popliteal lymph nodes 
were collected on day6 for subsequent experiments.  
2.6.6 Detection of IL-12p40-YFP by immunofluorescence staining 
For detection of IL-12p40-YFP by BM-DCs, day 8 BM-DCs that were further matured with 
LPS or left untreated, as described before, were used for Cytospins. Briefly, d 200ul of 
each cell suspension were added to a Cytospin slide chamber. The cytospins were 
centrifuged at 600rpm for 10 minutes using a Cytospin Universal centrifuge (Hettich, 
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Tuttlingen, Germany). Cytospins were fixed with 4% Paraformaldehyde (Sigma-Aldrich, 
Deisenhofen, Germany) for 15 minutes, washed twice with PBS. This was followed by 
blocking using 5% BSA for 30 minutes, the excess liquid was tipped off the slide. CD11c-
APC (N418, Biolegend) was diluted in 1% BSA and the cytospins were stained overnight. 
Next day, slides were washed 3 times with PBS and drop of Fluoromount-G (Serva 
Electrophoresis) was added per slide. Samples were stored at 4 °C until images were 
acquired using LSM 780 confocal microscope (Carl Zeiss Microimaging). For imaging of 
lymph nodes, popliteal lymph nodes were fixed using the PLP fixation protocol. Briefly, 
fresh lymph nodes were directly immersed in PLP fixation buffer and were left to rotate at 
4 °C overnight. Next day, they were washed with phosphate buffer three times for 5 
minutes and passed through a Sucrose gradient. First using 10% Sucrose, followed by 
20% then 30%. Lymph nodes were then washed once with phosphate buffer then placed 
in tissue-tek (Sakura) and kept at -80 °C till staining. Endogenous avidin and biotin in 
lymph node sections were blocked using Avidin/Biotin Blocking Kit (Vector Labs) and 
sections were stained with antibodies diluted in 2% FCS/PBS. Imaging was performed 
using LSM 780 (Carl Zeiss Microimaging). Quantitative image analysis was done using 
the Imaris software tools. The different labeled cells were localized using Imaris spot 
function and the relative distance was calculated using Excel software calculating the 
minimal distance in the X and Y planes.  
2.7 RNA sequencing of lymph node DC subsets 
Mice were injected with LPS/BM-DCs into the footpad and the popliteal and inguinal 
lymph nodes were collected after 48h. T and B cells were depleted by Dynabeads™ Biotin 
Binder (Invitrogen™) using Biotin-B220, CD3, and CD4 according to the manufacturer’s 
protocol. The negatively selected cells were sorted for different migratory DC subsets 
using a BD FACS Aria III (precision: single-cell; nozzle: 100 μm). 100 cells for every 
population for in total 3 replicates were sorted into individual wells of a 96-well plate 
(Brand) filled with 4 µl lysis buffer (Takara). Cells were spun down, immediately chilled to 
4°C and stored at −80°C. All the following experimental steps were performed using the 
SMART-Seq® v4 Ultra® Low Input RNA Kit (Takara) with a quarter of the recommended 
reagent volumes. The PCR amplification was performed according to the manual using 
21 cycles. Libraries were quantified by QubitTM 3.0 Fluometer (ThermoFisher) and 
quality was checked using 2100 Bioanalyzer with High Sensitivity DNA kit (Agilent). 0.5 
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ng of each library was subjected to a tagmentation-based protocol (Nextera XT, Illumina) 
using a quarter of the recommended reagent volumes, 10 min for tagmentation at 55°C 
and 1 min extension time during PCR for multiplexing. After PCR, the libraries were 
purified using AMPure XP beads and eluted in 15 µl of resuspension buffer. Libraries 
were pooled and sequenced in paired-end mode on the NextSeq500 sequencer (IIIumina) 
using the Mid Output 2×75 cycle kit. 
2.8 RNA sequencing data analysis  
Base calling was done by the internal software of the NextSeq 500 sequencer "NextSeq 
Control/RTA v2” and bcl2fastq2 Conversion Software v.2 was used to demultiplex the 
pooled libraries and to convert the bcl files generated by the sequencer to standard fastq 
files for downstream analysis. The generated raw reads were processed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc) for assessing read quality, 
number of duplicates and presence of adapter sequences. After this, the Illumina Nextera 
adaptors were cleaved using cutadapt (Martin, 2011) (version 1.16) and resulting reads 
were further trimmed keeping a quality drop value below a mean of Q20. Further, the 
processed sequences were mapped to the mouse genome using the short-read aligner 
STAR (Dobin et al., 2013) (version-2.5.2b) with genome and annotation files retrieved 
from GENCODE (July 2017, GRCh38.p5, M16). For all the studied samples, the 
proportion of reads uniquely mapped to the mouse reference genome ranged between 
83% and 87% in total. The sequences aligning to specific genes were quantified using 
bedtools (Quinlan and Hall, 2010) subcommand intersect (version 2.15.0). Next, the 
differentially expressed genes were identified using DESeq2 (Love et al., 2014) (version 
1.18.1). Only the genes having a Benjamini-Hochberg corrected p-value below 0.05 were 
classified as significantly differentially expressed (DEGs). The data were visualized as 
MA plot using DESeq2’s function plotMA. The RNA-Seq data presented in this work has 
been deposited at the NCBI Gene Expression Omnibus (Edgar et al., 2002) and can be 
accessed through GEO series accession number GSE124677. For pathway analysis, the 
enrichment scores for pathways up or downregulated by endogenous migratory XCR1+ 
DCs was calculated using GOrilla analysis tool (Gene Ontology enRIchment anaLysis 
and visuaLizAtion tool). The data were plotted as FDR q-value after Benjamini and 
Hochberg correction of p-values. The threshold of significance was set at FDR q-value 
(0.05). 
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2.9 Quantitative real-time PCR 
cDNA libraries generated by the SMART-Seq® v4 Ultra® Low Input RNA Kit from the 
sorted endogenous migratory DC subsets were used. Quantitative real-time PCR was 
performed on cDNA using iTaq™ Universal SYBR® Green Supermix (Bio-Rad). 
Reactions were run on a real-time quantitative PCR system (Roche, LightCycler® 96) 
and 18S was used as housekeeping gene. Relative expression differences were 
calculated using the ΔΔCt method (Livak and Schmittgen, 2001). Primer sequences were 
as follows: 
Primer Sequence (5’ to 3’) 
18S Fwd GTAACCCGTTGAACCCCATT 
18S Rev CGCTACTACCGATTGGATGG 
Il12a Fwd AGCTCCTCTCAGTGCCGGTC 
Il12a Rev GGTCTTCAGCAGGTTTCGGG 
Il12b Fwd AGCAGTAGCAGTTCCCCTGA 
Il12b Rev AGTCCCTTTGGTCCAGTGTG 
Table 6. List of primer sequences used for Real-Time PCR. 
All primer sequences were synthesized by Sigma-Aldrich (Deisenhofen, Germany) and oligo’s were desalted and removed from 
truncated sequences by the manufacturer. (Fwd = forward primer, Rev = reverse primer) 
 
2.10 Statistical analysis 
Statistical analyses were performed using Prism 6.0 software (GraphPad Prism). The 
unpaired, two-tailed Student’s t-test was used, if data sets of two independent groups 
were normally distributed. The Wilcoxon signed-rank test was performed to analyze the 
relative distances between cells in lymph node sections generated from the Imaris 
software tool.  
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3 RESULTS 
3.1 XCR1+ CD103+ migratory DCs are the major source of IL-12 
production in draining lymph nodes in a DC vaccination setup 
 
3.1.1 YFP production by Yet40 mice is equivalent to IL-12p40 by in vitro generated 
BM-DCs 
We first wanted to test whether the production of YFP from the Yet 40 mice was a reliable 
measure of IL-12p40 production by DCs. To test that, we generated BM-DCs from Yet40 
mice using 10% GM-CSF and the cells were treated at day 8 with 100ng/ml LPS and left 
in culture for another 24h or left without stimulation as a control. Likewise, cells that were 
generated from C57BL/6 mice were stimulated with the same dose of LPS or left 
untreated. Following that the cells were stained for CD11c as a classical marker for DCs 
and MHC II as a marker for their maturation (Fig 3A). YFP was detected in the FITC 
channel without any further staining and the C57BL/6 cells were stained for IL-12p40 
production intracellularly. The cells were analyzed by flow cytometry and the production 
of YFP by the Yet40-BM-DCs was observed after 24h LPS-stimulation compared to 
untreated controls (Fig. 3B), which was of comparable levels to the IL-12p40 production 
by the C57BL/6 WT cells (Fig. 3C). The YFP production was also observed only after LPS 
treatment using immunofluorescence microscopy (Fig 3D). Thus, we decided to use the 
Yet40 mice for the analysis of endogenous IL-1240 production by the different DC subsets 
in the draining LNs and in spleen. 
 
3.1.2 Endogenous migratory dendritic cells are the major producers of IL-12p40 in 
the draining lymph nodes at steady state 
Next, we analyzed the popliteal, inguinal, auxiliary, cervical skin draining lymph nodes 
and the gut-draining mesenteric lymph node for production of IL-12p40. Using the same 
gating strategy, we found that only the CD11cint MHC IIhigh cells which are the migratory 
DCs were positive for YFP production at steady-state conditions in the skin draining and 
in mesenteric lymph nodes. The CD11chigh MHC IIint resident DCs, CD11cint MHC IIlow 
macrophages, CD11c- MHC IIhigh B cells, and the cells negative for both markers which 
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Figure 3 : YFP production by Yet40 mice is comparable to p40 intracellular staining. A. Representative flow cytometry plots of 
generated BM-DCs on day 8 from C57BL/6 or from Yet40 mice. Gated on live cells followed by doublet exclusion, then gated on 
CD11c+ MHC IIhigh DCs B,C. Representative flow cytometry plots (left) and graphs comparing % of cells producing (right) IL-12p40-
YFP (B) or IL-12p40 intracellularly (right) (C) by BM-DCs treated for 24h + or - LPS 0.5µg/ml. D. Confocal microscopy images of 
CD11c+ (blue) untreated BM-DCs (left) or LPS treated DCs (right) to detect YFP production (green).  Data are representative of three 
independent experiments. ***P < 0.0001, **p < 0.001, *p < 0.05. 
are the T cells and other cells in the lymph nodes were all negative for YFP production 
(Fig 4A). To confirm that these are indeed migratory cells, the same populations were 
analyzed in a Yet40.Ccr7-/- mouse. In such mice, only a minor population of CD11cint MHC 
IIhigh population was present. This population showed a small fraction of IL-12p40-YFP 
positive cells (Fig 4B). Interestingly, in the spleen the same CD11cint MHC IIhigh population 
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was also positive for YFP production in YFP.Ccr7+/+ mice and it was still present in the 
Yet40.Ccr7-/- mice (Fig 4C), indicating that this subset is not of migratory origin.  
 
Figure 4 : YFP production at steady-state in skin draining LNs and in spleen A. Representative flow cytometry plots of inguinal lymph 
node (left) and mesenteric lymph node (right) subpopulations gated based on their expression of CD11c and MHC II in a Yet40 
reporter mouse. Right side of the black arrows are histogram plots of IL-12p40-YFP production by each subpopulation. B, C. 
Representative flow cytometry plots of inguinal lymph node B. or spleen C. subpopulations gated based on their expression of CD11c 
and MHC II in a Yet40 reporter mouse or a Yet40.Ccr7-/- mouse. Right side of the black arrows are plots showing % of cells producing 
IL-12p40-YFP from the CD11cint MHC IIhigh subpopulation 
  
3.1.3 XCR1+ CD103+ Langerin+ dermal DCs are the major subset producing steady-
state IL-12p40-YFP in draining lymph nodes 
Migratory DCs subsets in the skin draining lymph nodes are comprised of three subsets: 
1) Langerin+ CD103- CD11b- Langerhans cells that migrate from the epidermis. 2) 
Langerin+ CD103+ CD11b- dermal cDC1s (dDCs) and 3) Langerin- CD103- CD11b+ 
dermal cDC2s. We checked for the production of IL-12p40-YFP by the three different 
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subsets. The Langerin+ CD103+ XCR1+ CD11b- dermal DCs were the major YFP 
producers (Fig 5A), in line with what Reinhardt and colleagues found out (Reinhardt et 
al., 2006). That was also the case in the mesenteric lymph nodes, while the CD103 
CD11b double positive population that was mainly implicated in tolerogenic functions did 
not produce any YFP (Fig 5B). In the spleen the CD11cint MHC IIhigh YFP producing 
population that we identified were of the CD8+ CD11b- subset (Fig5 3C). 
 
Figure 5 : YFP production by different DC subsets in LNs and in spleen A, B, C. Representative flow cytometry plots of inguinal lymph 
node A. mesenteric lymph node B. and spleen C. subpopulations gated based on their expression of CD11c and MHC II in a Yet40 
reporter mouse (Left panels). CD11cint MHC IIhigh cells were sub-gated based on CD103 (CD8a for spleen) and CD11b expression 
(Middle panels). Histogram plots of IL-12p40-YFP production by subpopulations based on CD103 (CD8a for spleen) and CD11b 
expression are shown (right panel) 
 
3.1.4 CFA injection augments IL-12p40-YFP production by CD103+ dDCs in the skin 
draining lymph nodes 
Since IL-12 is the most important cytokine for polarizing T cells towards a T helper 1 
response (Macatonia et al., 1995), we tested for IL-12p40-YFP production in vivo upon 
CFA injection which skews the T cell response towards a Th1 phenotype (Shibaki and 
Katz, 2002). The different DC subsets from the draining inguinal LN were analyzed 24h  
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Figure 6 : CD103+ migratory dDCs are the major IL-12p40-YFP producers after CFA injection A. Representative flow cytometry plots 
of inguinal lymph nodes subpopulations gated based on their expression of CD11c and MHC II (left) and graphs showing % of CD11cint 
MHC IIhigh migratory DCs and CD11chigh MHC IIint LN resident DCs in a Yet40 reporter mouse before and 24h after 50 µl CFA s.c. 
injection. B,C,D,E. Representative flow cytometry plots (left) and bar graphs (right) of % of cells producing IL-12p40-YFP from CD103+ 
mig dDCs B. LCs C. CD11b+ mig DCs D. in inguinal or cervical LNs, and CD11c+ MHC IIhigh DCs in spleen E. before and after 50 µl 
CFA s.c. injection. Data are representative of three independent experiments. **p < 0.001, *p < 0.05. 
 
after CFA injection s.c. in the flank of the mouse, and cervical LNs were used as a non-
draining LN control. The spleen subsets were also analyzed for any systemic response. 
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We observed an increase in CD11cint MHC IIhigh migratory DC population indicating their 
increased mobilization from the skin in response to CFA injection, this was not observed 
by resident DCs and not in cervical LNs (Fig 6A). The CD11cint MHC IIhigh Langerin+ 
CD103+ migratory dDCs were the major subset that increased YFP production after CFA 
injection (Fig 6B). This was only the case in the inguinal lymph node in comparison to the 
non-draining cervical LN (Fig 6B). The Langerin+ CD103- migratory LCs and Langerin- 
CD103- CD11b- migratory dDCs showed no such increase both in inguinal and cervical 
LNs (Fig 6C, D). Interestingly, in the spleen we noticed that the % of IL-12p40-YFP 
producing population was reduced (Fig 6E), this might indicate that this CCR7-
independent population in the spleen is rather tolerogenic and is reduced under 
inflammatory conditions. 
 
3.1.5 LPS-matured BM-DC injection enhances IL-12p40-YFP production by CD103+ 
dDCs in a time dependent fashion 
The fact that CD103+ dDCs were the major producers of IL-12p40 after CFA injection 
prompted us to test for IL-12p40 production after BM-DC injection where they are 
assumed to provide all the three signals required for Th1 induction; including IL-12 
production (Elster et al., 2016). BM-DCs that were stimulated with LPS for 4h and labeled 
with eFluor670 to distinguish them from endogenous DC subsets (Fig 7A) were injected 
s.c. in the flank and the YFP production was analyzed after 24h, 48h, or 72h from draining 
inguinal LNs. The spleen was analyzed also for any systemic response. LN cellularity was 
significantly increase compared to CFA injection (Fig 7B) and all migratory DC subsets 
increased in their migration compared to CFA (Fig 7C, D, E). YFP production was 
significantly increased only from CD103+ migratory dDCs over the three time points, and 
the production peaked at 72h (Fig 7B). The CD11b+ migratory and resident DCs did not 
increase their YFP production in contrast to stimulation of LN cells with LPS in vitro, 
indicating no direct effect of LPS attached to the injected BM-DCs on the endogenous DC 
subset of the recipient mice (Fig 7C). The Langerin+ CD103- LCs also showed no 
significant increase in YFP production (Fig 7D). Interestingly, unlike what we previously 
observed (Voigtlander et al., 2006), YFP production was observed from the injected BM-
DCs over the indicated time points (Fig 8A). One possible explanation is that the YFP 
half-life is longer than IL-12p40 (Lorang et al., 2001), and thus the YFP signal observed  
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Figure 7 : CD103+ migratory dDCs are the major IL-12p40-YFP producers after LPS-matured BM-DC injection A. Inguinal LNs, 
cervical LNs and spleen were analyzed after LPS (0.5 µg/ml)-matured, eFlour670 labeled.BM-DC s.c. flank injection B. Graph showing 
inguinal LN cell count before or 24h after CFA injection compared to 24h, 48h, 72h, after LPS.BM-DC injection C,D,E. Graphs showing 
absolute counts of migratory CD11c+ MHC IIhigh DCs (left panels) and % of IL-12p40-YFP producing cells from CD11b+ mig dDCs C. 
CD103+ mig dDCs D. and DN mig DCs E. (right panels) after s.c. injection of WT.LPS/DC into Yet40 recipient mice (24, 48, 72h 
timepoints). Data are representative of three independent experiments. ***P < 0.0001, **p < 0.001, *p < 0.05. 
 
from BM-DCs is residual from the LPS stimulation before injection. The injected-BM-DCs 
did not reach the cervical LNs (Fig 8B), nor did they reach the spleen (Fig 8C) since no 
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eFluor670-labeled cells were observed. This indicates that the migration of the injected 
BM-DCs is limited to the draining LN nearest to the injection site. 
 
Figure 8 : Injected BM-DCs producing residual IL-12p40-YFP are restricted to the draining LN closest to the injection site A. 
Representative flow cytometry plots of inguinal lymph node subpopulations gated on CD11c and MHC II in a Yet40 reporter mouse 
(Left), CD11cint MHC IIhigh migDCs are either endogenous (eFluor670-) or injected BM-DCs (eFluor670+) (middle), Graph showing % 
of IL-12p40 YFP producing cells in the eFluor670+ BM-DC injected gate 24h, 48h, 72h, after s.c. flank injection in inguinal LN (right). 
B, C. Representative flow cytometry plots of inguinal lymph node subpopulations gated on CD11c and MHC II in a Yet40 reporter 
(left) then sub gated on either: CD11cint MHC IIhigh migDCs in (B) control cervical LN or CD11c+ MHC IIhigh DCs in (C) spleen for 
eFluor670+ cells (right). Data are representative of three independent experiments. ns= non-significant. 
  
3.1.6 Monocyte-derived DCs do not produce IL-12p40-YFP after LPS-BM-DC 
injection 
Previous studies have suggested that the major source of IL-12 production after CpG-
adjuvanted vaccine injection are monocyte-derived DCs (MoDCs) that migrate to lymph 
nodes in a CCR2-dependent fashion (De Koker et al., 2017). Using the same setup 
described in Fig 8A, we analyzed the CD11cint MHC IIhigh migratory and CD11chigh MHC 
IIint resident DC subsets in the skin draining LNs for the development of MoDCs and for 
their production of IL-12p40-YFP.  MoDCs were defined as CD11cint MHC IIhigh CD11b+ 
CD103- CD64+ and they down-regulate Ly6C expression (Zigmond et al., 2012) (Fig 9A).  
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Figure 9 : moDCs are not the source of IL-12p40-YFP after LPS-matured BM-DC injection A. Gating strategy for MoDCs in inguinal 
LN where CD11c+ MHC IIhigh eFluor670- endogenous migDCs (left) were sub gated based on CD103 and CD11b (middle). MoDCs 
are CD11b+ CD103- CD64+ and Ly6C- and appear only after LPS. BM-DC s.c. injection (right) B. Graph showing % of IL-12p40 YFP+ 
cells within the MoDCs in inguinal LN compared to cervical LN at steady state compared to 24h, 48h, 72h after LPS. BM-DC injection 
(left) and flow cytometry showing IL-12p40 YFP+ cells within the MoDC gate (right). C. Gating strategy of CD11c+ MHC IIint Ly6C+ 
CD64+ monocytes that appear after s.c. BM-DC injection (left), and graph showing their % in inguinal LN compared to cervical LN at 
steady state compared to 24h, 48h, 72h after LPS. BM-DC injection. Data are representative of two independent experiments. 
 
They appeared in the CD11cint MHC IIhigh migratory compartment in the 24h and 48h time 
points post-BM-DC injection and started disappearing in the 72h time point (Fig 9B). No 
IL-12p40-YFP production was observed by MoDCs (Fig 9B), indicating the difference in 
the source of IL-12 in our BM-DC injection setup from CpG immunizations. Also, within 
the CD11chigh MHC IIint resident gate, a monocytic population that was CD11b+ CD103- 
CD64+ Ly6C+ appeared in the inguinal LNs next to the injection site, and not in the non-
draining cervical LNs. The presence of this population peaked at 48h then declined again 
at 72h but no IL-12p40-YFP production was observed (Fig 9C). 
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3.1.7 Increased production of IL-12p40-YFP by XCR1+ CD103+ dDCs is similar for 
LPS- or CPG- matured BM-DCs 
Residual LPS remaining on the surface of the injected BM-DCs might be responsible for 
the increased IL-12p40-YFP production by XCR1+ CD103+ dDCs (Schwarz et al., 2014). 
 
 
 
Figure 10 CpG matured BM-DCs induce IL-12p40 YFP production by CD103+ migratory dDCs similar to LPS matured BM-DCs A. 
Graph showing inguinal LN cell count at steady state, 72h after CpG.BM-DC s.c. injection, or 72h after LPS.BM-DC s.c. injection 
B,C,D. Graphs showing absolute counts of migratory CD11c+ MHC IIhigh DCs (left panels) and % of IL-12p40-YFP producing cells 
from CD11b+ mig dDCs C. CD103+ mig dDCs D. and DN mig DCs E. (right panels) after s.c. injection of LPS.BM-DC or CpG.BM-DC 
into Yet40 recipient mice (72h). Data are representative of three independent experiments. ***P < 0.0001, **p < 0.001, *p < 0.05. 
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To rule out that this is the only possibility in our system, we tested the YFP production at 
72h by endogenous DC lymph node subsets after the injection of eFluor670-labeled CpG-
matured BM-DCs. Unlike the surface Toll-like receptor 4 that recognizes LPS, CpG acts 
on the intracellular Toll-like receptor 9 thus test for the surface LPS problem. Similar to 
LPS-BM-DC injection, LN cellularity significantly increased in a similar fashion as the 72h 
timepoint after LPS-BM-DC injection (Fig 10A). The migration of all CD11cint MHCIIhigh 
DC subsets was increased, while IL-12p40-YFP production was significantly induced only 
by the CD103+ migratory dDCs (Fig 10B, C, D). This indicates that LPS attached to the 
injected BM-DCs is not the only mechanism that induces IL-12p40-YFP production by 
CD103+ migratory dDCs. 
 
3.1.8 IL-12p35 subunit and IL-12p70 was not detectable by flow cytometry  
IL-12p40-YFP production was observed at steady state from CD103+ XCR1+ migratory 
dDCs, CD103 CD11b double positive migratory DCs in skin-draining and mesenteric LNs 
respectively, and from CD11cint MHCIIhigh CD8+ DCs in the spleen. And as mentioned  
 
Figure 11 : Flow cytometry staining of IL-12p35 and IL-12p70 proved difficult A. Representative flow cytometry plot of day 8 BM-DCs 
sub gated on CD11c+ MHC IIhigh mature DCs. Right side of the black arrow is a histogram plot of IL-12p35 production (clone 4D10p35) 
by WT LPS. BM-DCs compared to Il12a-/- LPS.BM-DCs. B. Histogram plot for IL-12p70 production (clone R2-9A5) gated on CD11c+ 
MHC IIhigh LPS-matured BM-DCs C. Histogram plot of IL-12p70 production (clone R2-9A5) by WT LPS. BM-DCs compared to Il12a-/- 
LPS.BM-DCs.  
 
before, studies have shown that the p40 molecule can form homodimers that acts as an 
IL-12 antagonist (Gillessen et al., 1995). The p35 subunit (Il12a) of the Th1 functional IL-
12p70 molecule proved difficult to detect by flow cytometry from in vitro LPS-matured BM-
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DCs (Fig 11A). And while the staining with the IL-12p70 (rat-IgG2b clone R2-9A5) 
antibody appeared to be positive on LPS-matured BM-DCs (Fig 11B), the same positive 
population appeared in LPS-matured BM-DCs from Il12a-/- mice (Fig 11C). This indicated 
that this antibody was nonspecifically binding to the IL-12p40 molecule. Therefore, we 
decided to switch to a system where we can study the dynamics of Th1 induction by a 
transgenic T cell population and monitor the dependency of such a response on IL-12 
production from either the injected BM-DCs or the endogenous migratory and resident 
DC subsets.  
 
3.2 XCR1+ CD103+ migratory DCs and not vaccine DC are the source of 
IL-12 for Th1 polarization and partly for antigen presentation 
3.2.1 LPS-matured antigen-loaded BM-DCs induce Th1 responses by CD4+ T cells 
in draining lymph nodes and in spleen 
To study the dynamics of IL-12p70 requirement for Th1 induction after BM-DC injections, 
we first injected T cells intravenously into C57BL/6 WT mice that have a transgenic TCR 
which only recognizes the OVA peptide from chicken egg white presented on MHC II 
molecules on APCs (Barnden et al., 1998). The OT-II cells also carried the congenic 
Thy1.1 (CD90.1) marker to be traceable in C57BL/6 WT mice with Thy1.2 background. 
Next day, OVA-loaded, LPS-matured BM-DCs (OVA-LPS/BM-DC) were injected s.c. in 
the flank or in the footpad and the inguinal or popliteal LNs were collected respectively as 
the closest draining LNs on day 6. Spleens were also collected to analyze the systemic T 
cell response (Fig 12A). Th1 polarization was tested by analyzing the lymphoblast gate 
for the presence of CD4+ OT-II. Thy1.1 T cells. These cells were analyzed for the 
production of IL-2, IFN- and IL-13 by intracellular staining (Fig 12B). We first observed 
that an effective T cell response required the injection of at least 106 BM-DCs per flank. 
Injecting 2*105 BM-DCs caused a significant increase in LN cellularity but were not 
enough to induce antigen specific T cell expansion (Fig 12C) as indicated by CD4+ OT-II. 
Thy1.1 T at day 6 which was similar to injecting T cells and no BM-DCs and by their 
minimal IL-2 production (Fig 12C). This was also the case after double injections of 2*105 
BM-DCs (Fig 12C). Upon injecting 106 BM-DCs per flank, we noticed a significant 
increase in LN cellularity and in CD4+ OT-II. Thy1.1 expansion in the skin draining LNs 
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after 6 days when compared to injecting OT-II. Thy1.1 cells only, where the injected 
population dies out at day 6 (Fig 12C). 
 
 
Figure 12 : LPS-OVA/BM-DCs induce CD4+ OT-II Thy1.1+ T cell expansion in draining lymph node A. OT-II+.Thy1.1+ T cell priming 
analyzed in popliteal or inguinal LNs and in spleen after 6 days of OVA (10 µM)-loaded, LPS (0.5 µg/ml)-matured BM-DC (OVA-
LPS/DC) s.c. footpad or flank injection. B. Gating strategy of CD4+ OT-II Thy1.1+ T cells, gated on live blasts followed by doublet 
exclusion, then gated on CD4+ Thy1.1+ T cells, IL-2 producing CD4+ Thy1.1+ T cells are shown on the right. C. Graphs comparing 
lymph node cell counts (left), frequency of injected OT-II+.Thy1.1+CD4+ T cells (middle) and percentage of IL-2 producing cells (right) 
after s.c. injection of 106 OVA-LPS/DC single injection (grey bars), 2*105 OVA-LPS/DC single injection (red bars), or 2*105 OVA-
LPS/DC double injection, compared to T cell injection alone (black bars) into C57BL/6.WT recipient mice. Data are representative of 
three independent experiments analyzing at least 5 mice per group. ***P < 0.0001, **p < 0.001, *p < 0.05. 
 
The proliferation of these cells was also traced by CTV dilution and they showed a 
significant increase in proliferation when compared to CTV labeled CD4- injected cells. 
This indicates their expansion in an antigen-dependent manner (Fig 13A). IL-2 and IFN-
 production was analyzed by intracellular flow cytometry and only the CTV negative 
population of CD4+ OT-II. Thy1.1 T cells were producing both cytokines, indicating their 
polarization to a Th1 profile (Fig 13B). Also, only a minor population was producing IL-13 
indicating no shift towards Th2 T cell response (Fig 13B). 
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Figure 13 : Proliferation and cytokine production by CD4+ OT-II Thy1.1+ T cells after LPS-OVA/BM-DC injection A. Representative 
flow cytometry plot of OT-II+.Thy1.1+CD4+ T cells in popliteal LN (left), and histogram of their proliferation based on CellTrace™ Violet 
(CTV) dye dilution by CD4+ OT-II Thy1.1+ T cells (red line) compared to other CTV-labeled cells (blue line) (right). B. Representative 
flow cytometry plots of IFN-, IL-2, or IL-13 producing OT-II+.Thy1.1+CD4+ T cells versus CTV labeling  
 
Surprisingly, we also observed a significant population of proliferating CD4+ OT-II. Thy1.1 
T cells in the spleen even though no injected BM-DCs arrive in the spleen as indicated in 
Fig 9C, indicated by their CTV dilution profile (Fig 14A). This population expanded equally 
as CD4+ OT-II. Thy1.1 T cells in the draining lymph nodes (Fig 14B) and showed more 
Th1 polarization indicated by their significantly increased IL-2 and IFN- production 
compared to the CD4+ OT-II. Thy1.1+ T cell population in the draining lymph node (Fig 
14C). No substantial levels of IL-13 producing cells were observed (Fig 14C). Additionally, 
these cells showed a higher level of proliferation as indicated by the % of CTV-ve cells and 
higher ratio of effector T cells/ naive T cells based on expression of the adhesion 
molecules CD44 and CD62L (Fig 14D). The cellular source responsible for antigen 
presentation to induce such robust Th1 response by the CD4+ OT-II. Thy1.1 T cells in the 
spleen is yet to be determined.  
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Figure 14 : CD4+ OT-II Thy1.1+ T cell expansion and cytokine production in the spleen A. Representative flow cytometry plot of OT-
II+.Thy1.1+CD4+ T cells in the spleen (left), histogram of their proliferation based on CellTrace™ Violet (CTV) dye dilution by CD4+ OT-
II Thy1.1+ T cells (red line) compared to other CTV-labeled cells (blue line) (middle), and graph comparing the % of proliferating CD4+ 
OT-II Thy1.1+ T cells in the popliteal LN to the spleen (right). B,C. Graphs showing the percentage of CD4+ OT-II Thy1.1+ T cells (B) 
and of IFN-, IL-2, or IL-13 producing OT-II+.Thy1.1+CD4+ T cells (C) in the popliteal or inguinal LN (grey bars) compared to the spleen 
(red bars). D. Representative flow cytometry plot of CD62L+ CD44low naive T cells and CD62- CD44low effector T cells within the OT-
II+.Thy1.1+CD4+ T cell gate (left), and graph comparing the ratio of naive to effector T cells in the LNs (black bar) to the spleen (red 
bar) (right) Data are representative of three independent experiments analyzing at least 5 mice per group. **p < 0.001, *p < 0.05. 
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3.2.2 Migration of antigen-loaded BM-DCs is required for T cell expansion 
The arrival of injected BM-DCs was directly related with IL-12p40-YFP production and no 
increase in YFP production was observed in the distant LNs where no BM-DCs arrived. 
Therefore, we tested whether the migratory capacity of injected BM-DCs is 
.  
 
Figure 15 : Injected BM-DC migration is required for antigen-dependent T cell expansion and polarization A. OT-II+.Thy1.1+ T cell 
priming analyzed in popliteal or inguinal LNs and in spleen after 6 days of WT.OVA-LPS/DC or Ccr7-/-.OVA-LPS/DC s.c. footpad or 
flank injection into C57BL/6.WT recipient mice . B. Graphs comparing lymph node cell counts and frequency of injected OT-
II+.Thy1.1+CD4+ T cells in inguinal or popliteal LNs after s.c. injection of WT.OVA-LPS/DC (grey bars) or Ccr7-/-.OVA-LPS/DC (orange 
bars) compared to T cell injection alone (black bars) . C. Same as (B) but showing only frequency of injected OT-II+.Thy1.1+CD4+ T 
cells in spleen. Data are representative of three independent experiments analyzing at least 5 mice per group. ***P < 0.0001, 
**p < 0.001, *p < 0.05. 
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mandatory for antigen presentation or if they can hand over antigens to other migratory 
subsets in the skin. Using BM-DCs generated from Ccr7-/- mice that cannot migrate to the 
draining lymph node and remains trapped in the injection site, we used the setup 
described in Fig 12A to test for OT-II. Thy1.1 T cell response (Fig 15A). On day 6, the LN 
cellularity was significantly increased compared to no BM-DC injection and to a 
comparable level to injecting WT BM-DCs (Fig 15B). This can be attributed to the local 
inflammation at the injection site. On the other hand, no expansion of OT-II Thy1.1 T cells 
was observed similar to no BM-DC injection, indicating that antigen presentation by 
injected BM-DCs takes place only when they reach the draining LN (Fig 15B). We also 
observed no OT-II Thy1.1 T cells in the spleens (Fig 15C), which indicates that the 
response does not disseminate systemically unless the T cells get primed first in the 
draining LN.  
 
3.2.3 IL-12p70 production by injected BM-DCs is not required for a Th1 response 
As mentioned, DCs in clinical trials that are matured in the presence of IL-1β/TNFα/IL-
6/PGE2-containing cytokine cocktail show desirable anti-tumor TH1 responses despite 
the fact that they have a reduced ability to produce IL-12p70 (Lee et al., 2002; Schuler-
Thurner et al., 2002). Therefore, we decided to test whether IL-12 lacking BM-DCs would 
be capable of inducing a proper Th1 response in our system. To this end, again we used 
the same setup described previously in Fig12A but injected Il12a-/- BM-DCs instead of 
WT BM-DCs to check for IL-12 requirement (Fig 16A). Surprisingly, the exogenous IL-12 
production was not needed for Th1 induction. As shown with WT BM-DC injections, the 
LN cellularity and the CD4+ OT-II. Thy1.1 T cell expansion was of comparable levels on 
day 6 (Fig 16B). Also, there was no significant reduction in IL-2 and IFN- production and 
no increase in IL-13 production compared to WT BM-DCs injection (Fig 16C). The robust 
Th1 response previously observed in the spleen also remained unchanged with 
significantly higher levels of IL-2 and IFN- cytokine production compared to LNs (Fig 
16D). 
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Figure 16 : IL-12p70 production by endogenous recipient DCs is required for required for antigen-dependent T cell expansion and 
Th1 polarization A. OT-II
+
.Thy1.1
+
 T cell priming analyzed in popliteal or inguinal LNs and in spleen after 6 days of WT.OVA-LPS/DC 
or Il12a
-/-
.OVA-LPS/DC s.c. footpad or flank injection into C57BL/6.WT recipient mice . B. Graphs comparing lymph node cell counts 
and frequency of injected OT-II
+
.Thy1.1
+
CD4
+
 T cells in inguinal or popliteal LNs after s.c. injection of WT.OVA-LPS/DC (grey bars) 
or Il12a
-/-
.OVA-LPS/DC (blue bars) compared to T cell injection alone (black bars). C,D. Graphs comparing percentage of OT-
II
+
.Thy1.1
+
CD4
+
 IFN-, IL-2, or IL-13 producing cells in LNs (C) or spleen (D) after s.c. injection of WT.OVA-LPS/DC (grey bars) or 
Il12a
-/-
.OVA-LPS/DC (blue bars). Data are representative of three independent experiments analyzing at least 5 mice per group. 
***P < 0.0001, **p < 0.001, *p < 0.05. 
 
3.2.4 Endogenous IL-12p70 production is required for Th1 polarization 
Since IL-12 production by the injected BM-DCs was not required for Th1 polarization, we 
proceeded by switching to a system lacking IL-12 production by the endogenous recipient 
 
62 
 
 
mice. We used the same setup from Fig 12A but using Il12a-/- mice as recipients. The 
injected BM-DCs were generated from either WT mice or from Il12a-/- mice (Fig 17A). On 
day 6, the LN cellularity was significantly increased because of BM-
 
 
Figure 17 : IL-12p70 production by endogenous recipient DCs is required for required for antigen-dependent T cell expansion and 
Th1 polarization A. OT-II+.Thy1.1+ T cell priming analyzed in popliteal or inguinal LNs and in spleen after 6 days of WT.OVA-LPS/DC 
s.c. injection into C57BL/6.WT recipient mice, WT.OVA-LPS/DC or Il12a-/-.OVA-LPS/DC s.c. injection into Il12a-/- recipient mice. B. 
Graphs comparing lymph node cell counts and frequency of injected OT-II+.Thy1.1+CD4+ T cells in inguinal or popliteal LNs after s.c. 
injection of WT.OVA-LPS/DC (grey bars) into C57BL/6.WT recipient mice, WT.OVA-LPS/DC (red bars) or Il12a-/-.OVA-LPS/DC (green 
bars) s.c. injection into Il12a-/- recipient mice compared to T cell injection alone (black bars). C,D. Graphs comparing percentage of 
OT-II+.Thy1.1+CD4+ IFN-, IL-2, or IL-13 producing cells in LNs (C) or spleen (D) after the same injections described in (B). Data are 
representative of three independent experiments analyzing at least 5 mice per group. ***P < 0.0001, **p < 0.001, *p < 0.05. 
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DC injection similar to WT recipients, and this was the case regardless of whether the 
BM-DCs were generated from WT or Il12-/- mice. However, the expansion of CD4+ OT-II. 
Thy1.1 T cells was significantly reduced only in Il12-/- recipients compared to WT 
recipients (Fig 17B), indicating the requirement of endogenous IL-12 for T cell expansion. 
The CD4+ OT-II. Thy1.1 T cells showed a reduced polarization towards a Th1 response, 
indicated by a significantly reduced IFN- production, the similar levels of IL-2 production, 
and a non-significant increased tendency for IL-13 production as seen by intracellular 
staining (Fig 17C). However, this reduction in Th1 response was not observed in the 
spleens of Il12-/- recipients. This was indicated by no significant reduction of IL-2 or IFN-
 production similar to spleens of WT recipient mice (Fig 17D). This suggests that the yet 
unexplained Th1 response in the spleen is most likely propagated in an IL-12 independent 
manner.  
 
3.2.5 A migratory CCR7+ DC provides the third signal for a Th1 response 
Since IL-12 production from endogenous cells of the recipient mice were required for an 
optimum Th1 polarization, we wanted to pin down which cellular subset is producing it. 
We first tested whether the endogenous subset is of migratory or of lymph node-resident 
origin. Using the same setup from Fig12A, Il12a.Ccr7-/- recipient mice that lack both IL-12 
production and endogenous migratory capacity towards the draining LNs were injected 
with BM-DCs generated from Il12a-/- animals (Fig 18A). 
In this setup, the LN cellularity was significantly increased as observed before. 
Interestingly though, CD4+ OT-II. Thy1.1 T cells expanded in a similar fashion as WT 
recipients (Fig 18B). Even though Il12a-/- recipient mice showed a reduction in CD4+ OT-
II. Thy1.1 T cells before (see Fig 17B). Nevertheless, the CD4+ OT-II. Thy1.1 T cells were 
incapable of adopting any T cell polarization phenotype. This is indicated by a complete 
abolishment of IFN- and IL-13 production and a minor fraction of IL-2 producing cells 
(Fig 18C). Also, only a minor population of CD4+ OT-II. Thy1.1 T cells was present in the 
spleens of Il12a.Ccr7-/- mice with significantly reduced IL-2 and IFN- production 
compared to Il12a-/- recipient mice (Fig 18D). However, this reduction was less 
significantly pronounced in the spleen compared to the LN, with significant IFN- 
production observed in the spleen (Fig 18D). 
 
 
64 
 
 
3.2.6 Endogenous migratory CCR7+ cells substantially contribute to antigen 
presentation 
One possible explanation for the observed reduction in IFN- and IL-2 production in 
Il12a.Ccr7-/- recipient mice compared to mice lacking Il12a only is that endogenous 
migratory DCs are required for antigen presentation also. We used MHC class II-/- 
recipient mice and injected WT BM-DCs to study this (Fig 18A). Due to a general lack of 
CD4+ T cells in these mice, the LN cellularity was significantly reduced compared to all 
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Figure 18 : An endogenous migratory CCR7+ DC contributes to antigen presentation and provides the third signal for a Th1 response 
A. OT-II
+
.Thy1.1
+
 T cell priming analyzed in popliteal or inguinal LNs and in spleen after 6 days of Il12a
-/-
.OVA-LPS/DC into Il12a
-/-
.Ccr7
-/-
 recipient mice or WT.OVA-LPS/DC into MHC II
-/-
 recipient mice compared to WT.OVA-LPS/DC into Il12a
-/-
recipient mice. B. 
Graphs comparing lymph node cell counts and frequency of injected OT-II
+
.Thy1.1
+
CD4
+
 T cells in inguinal or popliteal LNs after s.c. 
injection of WT.OVA-LPS/DC into MHC II
-/-
 recipient mice (purple bars) or Il12a
-/-
.OVA-LPS/DC into Il12a
-/-
.Ccr7
-/-
 recipient mice (pink 
bars) compared to WT.OVA-LPS/DC into Il12a
-/-
recipient mice (red bar) and to T cell injection alone (black bars). C,D. Graphs 
comparing percentage of OT-II
+
.Thy1.1
+
CD4
+
 IFN-, IL-2, or IL-13 producing cells in LNs (C) or spleen (D) after the same injections 
described in (B). Data are representative of three independent experiments analyzing at least 5 mice per group. ***P < 0.0001, 
**p < 0.001, *p < 0.05. 
 
the previous setups at d6, and the CD4+ OT-II. Thy1.1+ T cell expansion was equally 
reduced as in Il12a-/- recipient mice (Fig 18B), no IFN- and IL-13 production was 
observed and only a minor fraction of cells produced IL-2 similar to Il12a.Ccr7-/- recipient 
mice (Fig 18C). Similarly, the population of CD4+ OT-II. Thy1.1 T cells present in the 
spleen showed significantly reduced IFN- production compared to Il12a-/- recipient mice 
(Fig 18D). Unexpectedly, a significant percentage of cells were producing IL-2 in this case 
(Fig 18D). These results suggest that endogenous migratory DCs substantially contribute 
to antigen presentation. Considering the results shown in Fig 16B, that T cell priming 
strictly depends on BM-DCs migrating to the lymph nodes and transfer of antigen in the 
skin can be excluded, our data suggest that transfer of antigen or MHC II/peptide 
complexes from BM-DCs to endogenous migratory bystander DCs occurs in the lymph 
node. This is in agreement with data showing that antigen transfer to an endogenous DC 
subset is required to enhance T cell response during DC vaccination (Kleindienst and 
Brocker, 2003). This antigen transfer substantially contributes to Th0 priming and is 
essentially required for Th1 polarization. 
 
3.2.7 XCR1+ CD103+ dDCs provide the third signal for Th1 induction after BM-DC 
injection in the draining lymph node 
So far, all the evidences point to XCR1+ CD103+ dDCs as the major producer of IL-12 for 
Th1 polarization in the BM-DC injection setup. This is based on YFP production by the 
Yet40 mice and by the exclusive requirement of IL-12 from an endogenous Ccr7-
dependent migratory DC source. To conclusively show that, we used Xcr1-Venus-DTR 
mice, where the XCR1+ CD103+ dDC subset can be conditionally depleted upon 
diphtheria toxin (DTX) injection (Yamazaki et al., 2013) (Fig 19A). We confirmed the 
depletion of this subset specifically in the draining lymph nodes and in the spleen after 
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DTX injection. In these mice, there was a slight reduction in LN cellularity 6 days after 
BM-DC injection while the CD4+ OT-II. Thy1.1 T cells expanded in a similar fashion as 
WT mice (Fig 19B). The production of IL-2 however was significantly reduced indicating 
an impairment in T cell priming and IFN- and IL-13 were not detected suggesting the 
dependency of T cells on XCR1+ CD103+ dDCs for Th1 polarization (Fig 19C). 
Interestingly, in the spleens of these mice the expanded CD4+ OT-II. Thy1.1 T cells 
showed a strong Th1 polarization profile indicated by robust production of IL-2, IFN- and 
no IL-13 This suggested that Th1 polarization in the spleen was not dependent on the 
XCR1+ CD8+ DC subset unlike the situation in the lymph node. 
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Figure 19 : XCR1+ CD103+ dDCs provide the third signal for Th1 induction after BM-DC injection only in the lymph node A. OT-
II+.Thy1.1+ T cell priming analyzed in popliteal or inguinal LNs and in spleen after 6 days of Il12a-/-.OVA-LPS/DC into Xcr1-DTR-venus 
recipient mice compared to WT.OVA-LPS/DC into C57BL/6.WT recipient mice. B. Graphs comparing lymph node cell counts and 
frequency of injected OT-II+.Thy1.1+CD4+ T cells in inguinal or popliteal LNs after s.c. injection of Il12a-/-.OVA-LPS/DC into Xcr1-DTR-
venus recipient mice (dark red bars) compared to WT.OVA-LPS/DC into C57BL/6.WT recipient mice (grey bar) and to T cell injection 
alone (black bars). C,D. Graphs comparing percentage of OT-II+.Thy1.1+CD4+ IFN-, IL-2, or IL-13 producing cells in LNs (C) or spleen 
(D) after the same injections described in (B). Data are representative of three independent experiments analyzing at least 5 mice per 
group. ***P < 0.0001, **p < 0.001, *p < 0.05. 
 
3.2.8 CpG maturation of BM-DCs induce Th1 polarization similar to LPS-BM-DCs 
The activation of bystander DCs by injected BM-DCs for IL-p production and 
contribution to antigen presentation suggests their interaction in the draining lymph  
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Figure 20: Presentation of surface bound antigen is not the cause of bystander DC activation. A. Representative flow cytometry plots 
for CFSE
-
 donor DCs (Activators) and CFSE
+
 bystander activated DCs (Targets) and the % of IL-12p40 producing cells upon using 
LPS (top), or CpG (bottom)-matured activators. Graphs showing the % of IL-12p40
+
 cells from untreated, LPS or CpG-matured 
activator DCs and their respective bystander activated target DCs in three independent experiments. B. Graphs comparing lymph 
node cell counts and frequency of injected OT-II
+
.Thy1.1
+
CD4
+
 T cells in inguinal or popliteal LNs after s.c. injection of WT.OVA-
LPS/DC (grey bars) or WT.OVA-CpG/DC (white bars) compared to T cell injection alone (black bars). C,D. Graphs comparing 
percentage of OT-II
+
.Thy1.1
+
CD4
+
 IFN-, IL-2, or IL-13 producing cells in LNs (C) or spleen (D) after s.c. injection of WT.OVA-LPS/DC 
(grey bars) or WT.OVA-LPS/DC (white bars). Data are representative of three independent experiments analyzing at least 5 mice per 
group. ****P < 0.00001 ***P < 0.0001, **p < 0.001, *p < 0.05. 
 
nodes. One possibility of DC-DC interaction leading to bystander activation is that LPS 
bound to TLR4 on the migrated BM-DCs is 'presented' to other DCs in the lymph node. 
Previous in vitro data from our lab indicated that LPS-matured BM-DCs can activate co-
cultured immature BM-DCs to secrete IL-12p40, while CpG matured BM-DCs were 
unable to show this effect (Fig 20A, B). These data suggest that LPS remains bound to 
surface TLR4 and can be 'presented' to bystander DCs, while CpG seems to be efficiently 
internalized by DEC-205/CD205 (Lahoud et al., 2012) to bind TLR9 within intracellular 
vesicles. We showed in (Fig 10C) that CpG matured BM-DCs induce bystander IL-12p40 
production similar to LPS matured BM-DCs. We next wanted to test whether CpG 
matured BM-DCs can also induce Th1 polarization in vivo. The use of CpG-matured, 
OVA-loaded BM-DCs (OVA-CpG/DC) provoked a similar lymph node swelling, OT-
II+.Thy1.1+ CD4+ T cell expansion (Fig 20C) and IFN- frequencies as observed after 
OVA-LPS/DC injection, while the frequency of IL-2+ OT-II cells was slightly reduced, and 
substantial amounts of IL-13 was observed (Fig 20D). These data indicate that injected 
BM-DCs possess additional mechanisms of bystander DC activation beyond the 
'presentation' of surface bound pathogen. Similar to OVA-LPS/DC injections, the robust 
Th1 response previously observed in the spleen also remained unchanged with 
significantly higher levels of IL-2, IFN- and negligible IL-13 production compared to LNs 
(Fig 20E). 
 
3.2.9 CD27-CD70 interactions might be involved in IL-12 independent Th1 priming  
BM-DCs generated from Il12a-/- mice induced similar Th1 polarization as WT BM-DCs. 
Also, IL12a-/- recipient mice showed a significant reduction in Th1 polarization however 
there was a residual Th1 polarization that was not present in Il12a.Ccr7-/-, MHC II-/-, and 
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Xcr1.venus-DTR mice. This prompted us to check for possible IL-12 independent Th1 
priming pathways. One of the reported pathways that are involved in providing the third 
signal for T cells is the interaction of the TNF receptor family member CD27 on T cells 
and its ligand on APCs namely the CD70 molecule (Sanchez and Kedl, 2012; Soares et 
al., 2007).  
 
Figure 21 : CD27-CD70 interactions might be involved in IL-12 independent Th1 priming.  A. Flow cytometry plot of day 8 C57BL/6.WT 
BM-DCs before and after 6h of LPS treatment showing CD11c+ MHC IIint immature DCs (black), CD11c+ MHC IIhigh spontaneously 
matured DCs (red) in no LPS cultures and CD11c+ MHC IIhigh LPS matured DCs (green). B. Representative histogram (left) and graph 
of three independent experiments (right) of CD70 median FI in the populations described in (A). C. Graphs from inguinal LNs of 
C57BL/6.WT mice of CD70 median FI in CD103+, CD11b+, DN migratory DCs, or LN resident DCs at steady-state or 24h, 48h, or 72h 
after LPS. BM-DC injection. Data are representative of three independent experiments. *p < 0.05. 
 
First, we tested the expression of CD70 on generated BM-DCs that were stimulated for 
6h with LPS or left untreated as a control. We found an upregulation of CD70 on both the 
CD11chigh MHC IIhigh fully LPS-matured DCs and on the CD11chigh MHC IIint 
spontaneously-matured DCs (Fig 21A, B). On the other hand, within the CD11chigh MHC 
IIint lymph node resident DCs and the CD11cint MHC IIhigh migratory DCs; the XCR1+ 
CD103+ dDC subset expressed the highest levels of CD70 after LPS-BM-DC injection. 
This peaked 48h after injection and was decreased at the 72h time point (Fig 21C). These 
data may point to a role of CD70 on XCR1+ DCs for Th1 priming.  
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3.3 Vaccine DC communication with XCR1+ CD103+ migratory DCs 
induce their bystander activation and shifts them to a Th1 polarizing 
profile 
3.3.1 Kinetics of BM-DC entry and T cell expansion in the skin draining LN 
The fact that endogenous XCR1+ CD103+ dDC were the main subset responsible for 
providing signal three for Th1 polarization entails that the injected BM-DCs communicate 
with the endogenous DCs during the T cell priming process. We first wanted to study the 
dynamics of entry of the injected DCs and the kinetics of expansion of CD4+ OT-II. Thy1.1 
T cells in the draining lymph node. To this end OT-II. Thy1.1 T cells were injected i.v. and 
CTV-labeled LPS-BM-DCs generated from Il12a-/- mice were injected next day into the 
footpads of the mice. The popliteal LNs were collected and analyzed for the percentage 
of injected BM-DC and CD4+ OT-II. Thy1.1 T cells at 24h, 48h, and 72h time points 
respectively (Fig 22A). The entry of CTV-labeled LPS-BM-DCs following their injection 
peaked at 48h (Fig 22B), while expansion of T cells started at 48h and reached its peak 
levels at 72h (Fig 22C). This was evident also using confocal microscopy of popliteal LNs 
of Yet40 mice upon quantifying CTV-labeled BM-DCs and OT-II. Thy1.1+ T cells over the 
different timepoints in the T cell area of the lymph node. On the other hand, the number 
of IL-12p40+ cells remained constant, showing only a trend of higher frequencies at 48h 
(Fig 22D, 22E). We noticed that injected CTV-labeled BM-DCs were located in the T cell 
area and distinct clusters of OT-II. Thy1.1 cells were observed at the 24h time point (Fig 
22D, 22E). This is in line with what was previously observed by (Mempel et al., 2004) 
where during this period, T cells form long-lasting stable conjugates with DCs. At 48h and 
72h more CTV-labeled BM-DCs entered the LNs and OT-II. Thy1.1 T cell expansion was 
observed peaking at 72h. However, less clustering of BM-DCs with T cells was evident 
indicating the more motile, proliferative phase of the expanding T cells (Fig 22D, 22E).  
 
3.3.2 YFP+ endogenous DCs show patterns of communication with injected BM-
DCs at later time points  
We next wanted to study whether there are specific interactions between the injected-
BM-DCs and endogenous DCs of the recipient mice, presumably with the XCR1+ 
migratory DCs that were shown to provide the third signal for Th1 proliferation in a 
 
71 
 
 
bystander fashion. Using the same setup described in Fig 22A, we analyzed the relative 
distance of YFP+ endogenous DCs to the injected BM-DCs 24h, 48h, and 72h after their 
 
Figure 22 : Kinetics of BM-DC entry into the draining lymph node and T cell expansion. A. Popliteal LNs were analyzed by FACS and 
confocal microscopy. OT-II.Thy1.1+ cells were injected i.v., next day OVA (10 µM)-loaded, LPS (0.5 µg/ml)-matured CTV-lalebeld 
Il12a-/-.BM-DCs (CTV-OVA-LPS.DC) were injected s.c. into the footpad of Yet 40 recipients, mice were collected after 24h, 48h, or 
72h. B. Flow cytometry plot (left) and graph of three independent experiments (right) of percentage of CTV-OVA-LPS.DC in the LN 
24h, 48h, and 72h after injection. C. Flow cytometry plot (left) and graph of three independent experiments (right) of percentage of 
CD4+ OT-II.Thy1.1+ cells in the LN 24h, 48h, and 72h after injection. D. Representative immunofluorescence microscopy images of 
whole popliteal lymph nodes sections (upper row) and magnification of the T cell area after of OT-II+.Thy1.1+ T cell injection (red) + 
CTV labeled Il12a-/-.OVA-LPS/DC s.c. injection (yellow) into IL-12p40-YFP mice (green cells) (24, 48, or 72h after injection) E. Graphs 
showing number of OT-II+.Thy1.1+ T cells, CTV-labeled OVA-LPS/DC, and YFP+ endogenous Cs/popliteal lymph node cut 24, 48, 72h 
after DC injection. Data are representative of two independent experiments analyzing at least 4 mice per group. ***P < 0.0001, 
**p < 0.001, *p < 0.05.  
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injection within the T cell area of popliteal draining lymph nodes. As a comparison, the 
relative distance between total XCR1+ endogenous dDCs and injected-BM-DCs which 
includes the presumably bystander-activated CD103+ XCR1+ DCs and the tolerance 
inducing ones (Muzaki et al., 2016). Also, the relative distance of the unrelated CD11b+ 
DCs to injected-BM-DCs was used as a YFP- XCR1- endogenous DC control subset. The 
relative distance between CD11b+ and total XCR1+ endogenous DCs to injected DCs 
showed a tendency to increase at the 48h and 72h time points when compared to the 24h 
time point (Fig 23A). This is attributed to their random movement in the lymph node that 
gets enlarged at the 48h and 72h time point. On the other hand, the relative distance 
between YFP+ endogenous DCs and injected BM-DCs was significantly reduced at both 
48h and 72h time points compared to 24h (Fig 23A). This strongly points to a specific 
interaction between the YFP+ XCR1+ endogenous DCs with the injected BM-DCs that is 
initiated during the T cell proliferation phase.  
 
3.3.3 Cognate T cells and YFP+ endogenous DCs show patterns of communication 
at later time points 
If the YFP+ endogenous DCs are indeed receiving signals from the injected BM-DCs at 
later time points, we expected them to provide the third signal to T cells in a bystander 
fashion also at later time points during the T cell expansion phase. This was already 
indicated by the fact that IL-12p40-YFP peaked at the 72h (Fig 7C), indicating its 
requirement later in the expansion phase. To confirm that, we measured the relative 
distance of OT-II. Thy1.1+ T cells to YFP+ endogenous DCs and used the relative distance 
between OT-II. Thy1.1+ T cells and injected BM-DCs as a control representing cognate 
antigen recognition. The relative distance between T cells and BM-DCs showed a 
tendency to increase after 48h, which increased significantly at 72h, compared to the 24h 
time point (Fig 23B). This is due to the increase in LN size indicated before. On the other 
hand, the relative distance between T cells and YFP+ endogenous DCs was significantly 
reduced after 48h and 72h as compared to the 24h time point (Fig 23B). From these 
findings we concluded that a time-dependent three-way communication i) between the 
injected BM-DCs and cognate T cells, ii) the BM-DCs with YFP+ XCR1+ endogenous 
bystander cDC1s, and iii) YFP+ XCR1+ endogenous bystander cDC1s with the primed 
Th0 cells for further polarization into Th1 cells.  
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Figure 23 : YFP+ XCR1+ DCs interact with injected DCs and antigen-specific T cells at later time points. A. Graphs showing the 
relative distance of CD11b+ cells, XCR1+ cells, and YFP+ cells to CTV-labeled OVA-LPS/DC in the peripheral lymph nodes 24, 48, or 
72h after DC injection B. Graphs showing the relative distance of OT-II+.Thy1.1+ T cells to CTV-labeled OVA-LPS/DC or to YFP+ 
endogenous DCs in the peripheral lymph nodes 24, 48, or 72h after DC injection. Green arrow indicates the distance shift at 48h and 
72h compared to 24h. Data are representative of two independent experiments analyzing at least 4 mice per group. ***P < 0.0001, 
**p < 0.001, *p < 0.05. 
 
3.3.4 4-1BB and 4-1BBL interactions as a candidate signal driving DC-DC 
communication  
As mentioned earlier, one of the possible signals promoting DC-DC crosstalk is the 
interaction between the TNF receptor family member 4-1BB and its ligand 4-1BBL 
(Futagawa et al., 2002). We showed previously that both molecules are expressed on 
matured BM-DCs. This was confirmed on day 8 BM-DCs that were treated with LPS for 
6h compared to unstimulated control. 
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Figure 24 : 4-1BB and 4-1BBL interactions as a candidate signal driving bystander DC activation . A. Graphs of three independent 
experiments of 4-1BBL (left) or 4-1BB (right) median FI showing CD11c+ MHC IIint immature DCs (black), CD11c+ MHC IIhigh 
spontaneously matured DCs (red) in no LPS cultures and CD11c+ MHC IIhigh matured DCs after 6h LPS treatment (green). B,C. 
Graphs from inguinal LNs of C57BL/6.WT mice of 4-1BBL (B) or 4-1BB (C) median FI in CD103+, CD11b+, DN migratory DCs, or LN 
resident DCs at steady-state or 24h, 48h, or 72h after LPS. BM-DC injection. Data are representative of three independent 
experiments. 
 
A percentage of 4-1BB and 4-1BBL positive BM-DCs was observed on untreated control 
cells and 4-1BB was upregulated on the CD11chigh MHC IIint spontaneously-matured DCs 
and upon LPS treatment. Such upregulation was not observed by 4-1BBL (Fig 24A). 
Unfortunately, no 4-1BB positive population was detected within CD11chigh MHC IIint 
lymph node resident DCs and the CD11cint MHC IIhigh migratory DCs. And this did not 
change after LPS-BM-DC injection 24h, 48h,72h following the injection (Fig 24B). This 
was also the case when analyzing 4-1BBL within the lymph node DC subsets (Fig 24C). 
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3.3.5 Distinct transcriptional shifts are observed in migratory DC populations after 
LPS-BM-DC injection 
Apart from 4-1BB and 4-1BBL interactions as a possible signal for communication 
between injected BM-DCs and the different endogenous migratory DC subset, we wanted 
to test for the global transcriptional shifts that occur within these subsets and identify other 
possible interaction partners. We made use of next-generation sequencing technologies 
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Figure 25 : Sorting strategy for cDCs and MoDCs RNA sequencing. A. Gating strategy for migratory cDC1s, cDC2s and DN DCs in 
popliteal and inguinal LNs. CD11c+ MHC IIhigh Lin- (CD4- CD8- B220-) CTV- endogenous migDCs were sub gated based on XCR1 and 
CD11b into XCR1+ CD11b- cDC1s, CD11b+ XCR1- cDC2s, and XCR1- CD11b- DNs. B. Gating strategy for MoDCs from CD11c+ MHC 
IIhigh Lin- (CD4- CD8- B220-) CTV- endogenous migDCs. MoDCs were CD11b+ F4/80- CD64+ and Ly6C- and appear only after LPS. 
BM-DC s.c. injection (right). 
 
to study these changes. Briefly, we sorted CD11cint MHCIIhigh migratory XCR1+ CD11b- 
dDCs, CD11b+ XCR1- dDCs, and CD11b- XCR1- DCs (DN) at steady-state and 48h after 
injecting CTV-labeled LPS.BM-DC (Fig 25A). Also, CD11b+ CD64+ Ly6Clow inflammation-
induced MoDCs that we described in (Fig 9C) were also sorted at 48h (Fig 25B). Since 
MoDCs could not be detected in naive mice, we were lacking a direct related control for 
this population. Cells were sorted from pooled popliteal and inguinal LNs that were 
isolated from C57BL/6 mice after footpad injections. We chose the 48h time point based 
on the observed change in the relative distance between injected BM-DCs, endogenous 
YFP+ DCs and cognate Thy1.1+ T cells which started only at 48h, indicating that bystander 
activation of endogenous migratory DCs starts at this time point. RNA sequencing was 
performed on 100 sorted cells from each population. Principle component analysis (PCA) 
segregated the samples into three distinct groups. Each of the three cDC subsets 
clustered differently and shifted to a different direction after their bystander activation. 
MoDCs clustered close to CD11b+ dDCs and appeared further distant from bystander 
activated CD11b+ dDCs indicating a close relation (Fig. 26A). Gene ontology (GO) and 
pathway enrichment analysis for the differentially regulated genes in the XCR1+ dDC 
subset indicated a down-regulation of nucleosome organization, cellular development 
and, cellular differentiation pathways. Interestingly, genes promoting Th2 induction or 
Treg induction by DCs were included in these down-regulated pathways, together with 
genes involved in DC migration and genes that modulates the antigen presentation 
capacity of DCs. (Fig. 26B). We compared the differentially regulated genes from 
activated XCR1+ dDCs to steady-state XCR1+ dDCs, and likewise for CD11b+ dDCs and 
DN DCs. MoDCs were compared to activated CD11b+ dDCs. A total of 112 genes were 
significantly up- or down-regulated in at least one of the comparisons. The clusters of 
genes that were regulated in each comparison were very different for each DC subset 
(Fig. 26C). This may indicate that the enlarged lymph nodes deliver distinct signals to 
individual DC subsets that cannot be explained simply by a general inflammatory situation 
that should activate similar transcriptional responses in each DC subset. Genes such as 
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Figure 26 : Endogenous migratory DC subsets have distinct transcriptional changes after bystander activation by BM-DC injection. 
A. PCA for XCR1+, CD11b+ and XCR1- CD11b- endogenous migratory DCs from popliteal lymph nodes nodes before and 48h after 
immunization, and CD11b+ CD64+ Ly6C-MoDCs compared to CD11b+ DCs after immunization. B. Genes downregulated in XCR1+ 
DCs 48h after immunization according to the GOrilla analysis tool. Only pathways with a Benjamini and Hochberg corrected p-value 
below 0.05 were considered. Green color: down in XCR1+ DCs only; orange color: down in XCR1+ DCs and MoDCs. C. Heatmap plot 
of the 112 genes that are at least 1.5-fold differentially expressed in one comparison (red: upregulated; blue: downregulated). Plotting 
was done using Clustvis web tool, Clustering was performed using Pearson’s correlation and average linkage. D. Heat map showing 
differential expression of selected immune-related genes before and after immunization; heat map was generated as described in C. 
E. qPCR analysis of Il12a and Il12b expression in the all sorted DC subsets before and after immunization N=3±s.e.m.  
 
H2-M2 which is a TAP-independent surface-expressed MHC class Ib molecule (Moore et 
al., 2004), Slamf7 which is a signaling lymphocytic activation molecule family member 
known to activate NK cells in a homotypic fashion (Cruz-Munoz et al., 2009), Vmp1 
involved in autophagy (Zhao et al., 2017), and Tmem79, a transmembrane protein 
involved in the lamellar granules secretory system and skin barrier function (Sasaki et al., 
2013), were specifically up-regulated on XCR1+ bystander dDCs which might be involved 
in cell-cell communication. The bystander DCs also down-regulated genes not related to 
Th1 induction, such as TGF- signaling required for Treg induction or promoting Th2 and 
Th9 immunity (Fig. 26D). Il12a and Il12b did not appear up-regulated by XCR1+ dDCs in 
the RNA-seq analysis. Nevertheless, the up-regulation of Il12a and Il12b on bystander 
activated XCR1+ dDCs was confirmed with real-time PCR and both genes were found to 
be specifically up-regulated on the designated XCR1+ subset and not on any of the other 
bystander activated DC subsets (Fig. 26E). We assume that not all endogenous migratory 
XCR1+ DCs are activated to become bystander DCs since they may carry out their 
tolerogenic functions (Muzaki et al., 2016). This may cause a dilution of transcriptional 
changes serving as bystander signals such as the IL-12 signal and only strongly regulated 
genes become visible. Together, the transcriptional profiling of XCR1+ migratory 
bystander cDC1s is characterized by a down-regulation of genes involved in other 
polarizations than Th1 and the up-regulation of genes such as Il12a and Il12b required 
for IL-12p70-mediated Th1 polarization.  
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4 DISCUSSION 
DCs are the dominant immune cells to induce T cell priming in vivo. Also, the instruction 
of T helper cell responses by DCs providing polarizing signals has become generally 
accepted. Among the Th1 instructing cytokines, IL-12p70 plays a prominent role. Here 
we addressed, whether the priming capacity and polarizing IL-12p70 signals are derived 
from injected vaccine DCs. We employed s.c. injection of BM-DCs into mice as a model 
to test different chimeric situations where injected BM-DCs and recipient mouse strains 
were bearing different genetic deficiencies. Our model is close to clinical studies where 
human MoDC vaccines are tested against tumors, due to the fact that GM-CSF generated 
BM-DCs are monocyte-derived (Lutz et al., 2017).  
Our data revealed that s.c. injected vaccine BM-DCs only partially contribute to antigen 
presentation at an early stage (24h) and they do not contribute to Th1 polarization. A 
major part of antigen presentation for Th0 induction and the entire capacity for Th1 
polarization is mediated by endogenous XCR1+ migratory bystander cDC1s at later time 
points (48-72h). However, BM-DCs migration to the draining lymph node is strictly 
required and bystander activation for IL-12 production seems to occur in the lymph node. 
Our findings argue for a step-wise process of priming naive T cells into an IL-2+ IFN--
Th0 phenotype by the injected DCs, followed by a communication between injected BM-
DCs and XCR1+ bystander cDC1s. Bystander contact includes transfer of antigen and 
initiation of IL-12p70 production. This period is followed by contacts of activated IL-12p70+ 
XCR1+ bystander cDC1s with the Th0 cells to continue antigen presentation and 
conversion into Th1 polarized cells. RNA sequencing allowed the identification of 
transcriptional changes during the conversion of endogenous migratory XCR1+ cDC1s 
into XCR1+ bystander cDC1s. Among those, DC genes known to polarize naive T cells 
into Treg or Th2/Th9 immune responses or to counteract IL-12 production were down-
regulated, while Th1 supporting genes were induced. 
4.1 Impact of the study on dendritic cell vaccination strategies 
The optimization of DC vaccination protocols has focused mainly on enhancing the 
activation of generated DCs (Morse et al., 2005; Tsang et al., 2005), their cytokine 
production profile (Okada et al., 2005), and their migration capacity (Turnis et al., 2010). 
Other studies attempted to combine the vaccine injection with adjusting the 
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immunosuppressive milieu of the tumor microenvironment to a more immunogenic one, 
for example by blocking inhibitory receptors such as PD-1/PD-L1 (Soares et al., 2015).  
In this study, we find that endogenous DCs are critically required to induce polarized Th1 
responses and enhance Th0 priming by vaccine DCs. We were able to identify XCR1+ 
endogenous migratory dDCs (cDC1s) as communication partners that take up the 
message delivered by the injected vaccine DC and are responsible for promoting full-
blown Th1 responses. This opens a new level of complexity when considering new 
strategies for vaccine DC optimization. The requirement of endogenous DCs for optimal 
anti-tumor DC vaccination is of clinical importance since these patients are treated with 
immuno-suppressive chemotherapy and are subjected to -irradiation that will affect 
endogenous DC populations. In contrast, the use of CTLA-4 and PD-1 targeted 
checkpoint inhibitors would not negatively affect endogenous DCs. 
This study also sheds light on the question why the IL-1β/TNF/IL-6/PGE2 matured 
vaccine DCs are successful in Th1 priming, despite a lack of IL-12 producing capacity 
(Gross et al., 2017; Lee et al., 2002; Schuler-Thurner et al., 2002). The addition of PGE2 
is known to improve the yield and function of human DCs matured with TNF-α, IL-1β, and 
IL-6, and skews them towards a Th1 phenotype (Jonuleit et al., 1997). In vitro experiments 
however showed that this cocktail skewed T cells towards Th2 responses (Kaliński et al., 
1997), and this was attributed to PGE2 blocking the formation of the bioactive IL-12p70 
heterodimer (Kalinski et al., 1998).  This always contradicted the obvious clinical outcome 
of such a maturation protocol. 
The fact that Th1 priming is not dependent on IL-12 secretion by monocyte-derived DC 
immunizations has been reported in pathologies other than tumor; such as in L. major 
challenged mice (Ramirez-Pineda et al., 2004). In our study, IL-12 production strongly 
supported Th1 polarization, and the XCR1+ migratory cDC1s were the mediators of this 
function. These cells appear to take over the Th1 polarization function from the injected 
BM-DCs at a later stage of the T cell response, when the initial antigen presentation phase 
is terminated and T cells enter their proliferative phase (Mempel et al., 2004; Miller et al., 
2004).  
4.2 Steady-state production of IL-12p40 by CD103+ migratory DCs 
Several studies have shown before that CD103+ migratory DCs were capable of 
producing IL-12p40 (Il12b) at steady-state in the skin draining LNs (Reinhardt et al., 
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2006), in mesenteric and hepatic LNs (Everts et al., 2016), and in mediastinal LNs 
(Conejero et al., 2017). This was clearly demonstrated also in our study by FACS, RNA 
sequencing and real time PCR. Two of these reports suggested that this steady-state 
Il12b production serves as a suppressor of Th2 and Th17 derived immune responses in 
a helminth infection model (Everts et al., 2016) and in a house dust mite allergy model 
(Conejero et al., 2017). These studies however only looked at the Il12b subunit using 
Yet40 mice (Reinhardt et al., 2006) and not at the bioactive IL-12p70 molecule (Macatonia 
et al., 1995). Homodimers formed from the Il12b subunit (p40)2 have been reported by 
several groups to have immunosuppressive effects and act as an antagonist to the Th1 
inducing IL-12p70 by binding to the IL-12 receptor and blocking its activity (Gillessen et 
al., 1995; Ling et al., 1995). Another group showed that UV irradiated DCs and 
macrophages failed to produce IL-12p70 and induce Th1 cells but rather produced p40 
homodimers and failed to induce Th1 responses while maintaining Th2 priming 
capabilities (Schmitt and Ullrich, 2000). The fact that CD103+ cDC1s secrete Il12b at the 
steady-state and not the IL-12p70 heterodimer as indicated by our data suggests that 
Il12b is rather required for maintaining the tolerogenic functions of this DC subset 
(Coombes et al., 2007; Idoyaga et al., 2013) rather than preventing Th2 and Th17 
induction as claimed by these studies (Conejero et al., 2017; Everts et al., 2016). The 
expression profile of CD103+ migratory cDC1s in the Immgen database shows a similar 
profile with high levels of Il12b expression specifically by this subset and not by other LN 
resident and migratory DC subsets (Miller et al., 2012), and no expression of the Il12a 
molecule. Upon activation of migratory cDC1s under an immunizing condition, they 
produce Il12a which forms the IL-12p70 required for Th1 priming. It is also possible that 
such Il12b steady-state production maintains migratory cDC1s in a “ready” state for IL-
12p70 production and Th1 priming. Interestingly, we see steady-state production of Il12b 
by CD8+ spleen resident cDC1s which further supports the tolerogenic function of Il12b 
since they were shown to be responsible for iTreg induction in a TGF- dependent 
manner (Yamazaki et al., 2008). 
4.3 Control of immune response by resident XCR1+ compared to 
migratory XCR1+ cDC1s  
While both resident and migratory cDC1s share the expression of XCR1 (Crozat et al., 
2011) and were shown to have a unique cross presenting capability to CD8 T cells 
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(Hildner et al., 2008), the distinction of their functional capabilities is still unclear. In the 
context of viral infection, migratory cDC1s were shown to be required for priming of CD8 
T cells to occur (Allan et al., 2006). The antigen is then transferred to resident cDC1s 
which appear to cross present viral antigens at later stages of the response (Allan et al., 
2006); (Eickhoff et al., 2015). Imaging the viral response in the draining lymph node 
revealed that CD4 T cells and CD8 T cells were initially primed at different time points 
and cDC1s serve as platforms for CD4 T cell augmentation of CD 8 T cell response 
(Brewitz et al., 2017; Eickhoff et al., 2015).  
On the other hand, recent studies showed that the migratory cDC1s and not resident 
cDC1s were uniquely required for promoting tumor immunity. This included their active 
transport of tumor antigens to tumor draining lymph nodes and also their robust ability to 
activate naïve CD8 T cells ex vivo following sorting of the various cDC subsets (Roberts 
et al., 2016; Salmon et al., 2016). Migratory cDC1s appear to transfer a fraction of the 
tumor antigen they are bearing to other migratory and lymph node resident DCs. 
However, despite the transfer, isolation of the draining lymph node and testing the 
different DC subsets ex vivo showed that only migratory cDC1s and not resident cDC1s, 
have the capacity to stimulate naive CD8+ T cells against tumor-associated model 
antigens (Roberts et al., 2016; Salmon et al., 2016). 
In our setup, we find that migratory cDC1s and not resident cDC1s are responsible for 
promoting Th1 responses later in the immune response, which suggests that unlike in 
viral responses, BM-DC immunization promotes an immune response resembling the 
tumor situation in migratory cDC1s. What mechanistically differentiates the antiviral from 
the antitumor response is yet to be determined. 
4.4 Transfer of antigens from vaccine DCs to XCR1+ migratory DCs 
Apart from their requirement for promoting Th1 polarization, we also find that CD103+ 
XCR1+ migratory cDC1s were required for antigen presentation later in the T cell 
response, indicating antigen transfer from the injected BM-DCs. This is not caused by 
handover of antigen to CD103+ XCR1+ migratory cDC1s in the skin such as observed for 
injected apoptotic DCs (Desch et al., 2011; Inaba et al., 1998), since no T cell priming or 
polarization occurred when antigen-loaded Ccr7-/- BM-DC were used for immunization. 
Antigen transfer in the lymph node was reported to occur mainly from migratory DCs to 
CD8+ resident DCs after viral infections (Allan et al., 2006; Eickhoff et al., 2015) or via the 
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conduit system for particulate antigens (Gerner et al., 2015; Sixt et al., 2005). Other 
reports suggest that migratory DCs also, and especially CD103+ XCR1+ migratory cDC1s, 
can capture archived antigens from lymphatic endothelial cells (LEC) in the draining 
lymph nodes when the antigen is cell-associated (Kedl et al., 2017). A similar scenario 
can possibly account for antigen transfer from vaccine DCs to CD103+ XCR1+ migratory 
cDC1s. The requirement for endogenous DCs to support optimal CD4+ T cell responses 
by DC-DC contacts in lymph nodes has been observed before, but the endogenous DC 
subset was not identified and further bystander function for Th1 polarization was not 
investigated (Kleindienst and Brocker, 2003). Several mechanisms of antigen transfer 
between different DC subsets have been suggested, for example: via trogocytosis (cross-
dressing) (Zhang et al., 2008), or via exosomes (Segura et al., 2007), both pathways have 
been implicated in the transfer of peptide-bound MHC molecules and also co-stimulatory 
molecules. MHC I peptide transfer has been show to involve trogocytosis, where direct 
cell to cell contact between the donor and the recipient cells, and not exosome exchange 
was observed (Wakim and Bevan, 2011). Since the study from Kleindienst and 
colleagues showed that direct cell to cell contact is required for antigen transfer; 
trogocytosis is the more probable mode of antigen transfer (Kleindienst and Brocker, 
2003). Our data suggest that migrated BM-DCs transfer antigen and Th1 polarizing 
information specifically to XCR1+ bystander DCs in the lymph node. In contrast to IL-12 
production, the process of antigen transfer may not require transcriptional changes in the 
bystander DCs.  
4.5 IL-12 independent priming by XCR1+ migratory cDC1s 
We observed residual Th1 polarization capacity from XCR1+ migratory cDC1s even when 
they lacked IL-12 production capabilities as indicated by our Il12a-/- recipient experiments. 
The residual Th1 polarization was completely abolished when migratory DCs were absent 
in the Il12a.Ccr7-/-model, and specifically when the XCR1+ migratory cDC1s are lacking 
in Xcr1-venus-DTR mice. Although we were not able to identify the mechanism involved 
in such IL-12 independent priming, CD27-CD70 interactions is still a possible mechanism 
(Soares et al., 2007). CD70 expression was specifically upregulated on migratory cDC1s 
48h after LPS BM-DC injection compared to steady-state by flow cytometry. A study that 
used activating or blocking CD70 antibodies that were specifically targeted to the uptake 
receptor DEC-205 on cDC1s showed that CD70 promotes IL-12 independent IFN- 
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production by CD4 T cells. This effect was not seen on DCIR2 expressing CD11b+ cDC2s 
(Soares et al., 2007). It is possible that following antigen transfer from injected BM-DCs 
to migratory cDC1s, T cells receive IL-12 independent CD27-CD70 signals during 
recognition of the transferred antigen on the migratory cDC1s during the later phase of 
the response (48h). The fact that we see CD70 upregulation only at this timepoint might 
support this hypothesis. CD27-CD70 interactions might explain several models where IL-
12 absence did not abolish IFN- production (Jankovic et al., 2002; Yang et al., 1999), 
such as Il12b-/- mice that still showed substantial IFN- production after Toxoplasma 
gondii infections (Jankovic et al., 2002). This also might explain why patients with genetic 
deficiencies in IL-12 or IL-12 receptor are still able to produce IFN- and avoid infection 
with most intracellular pathogens (Fieschi et al., 2003). Another group showed that OX40, 
which is another TNF receptor family member, can augment the function of CD70 and 
this also is independent of IL-12 production by cDC1s (Sanchez and Kedl, 2012). 
4.6 CCR7 knockout as a model to study migratory DC functions 
Using the Il12a.Ccr7-/- mouse model, we noticed that despite the lack of Th1 priming and 
significantly lower IL-2 production capacity of T cells, there was a significant population 
of proliferating T cells. This can be explained by the abnormal LN structure and the 
perturbations of immune homeostasis observed in these mice (Forster et al., 1999). 
These mice are characterized by the lack of normal distribution of B cell follicles to the 
outer cortex as well as a paracortical T cell–rich area. They rather display an irregular 
distribution of B and T cells within the paracortex. Also, B cell follicles with considerably 
enlarged germinal centers were observed within the paracortex. It is possible that such 
an abnormal organization of the LN structure results in an increased likelihood of the 
“more fit” BM-DCs to meet their antigen specific T cell, where they are capable of 
providing signal 1 and 2 for the initial period of the T cell response. However, since the 
migratory cDC1s are lacking in this model, the response cannot be propagated and is 
blocked at the Th0 phase (Openshaw et al., 1995). The Th0 response is also limited since 
migratory cDC1s are partly required for antigen presentation.  
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4.7 How is the systemic response propagated? 
One finding that we were not able to explain in this study is the robust Th1 polarized 
response observed in the spleen, even though injected BM-DCs do not reach the spleen 
neither do they reach LNs that are far from the injection site, which indicates a confined 
immunization process. Thus, the source of antigen that causes such a response in the 
spleen remains unclear. Interestingly though, this response is not affected by the absence 
of Il12a, unlike the response in the LN, but is almost absent in MHC II-/- mice, which 
indicates that endogenous antigen presentation is initiated in the lymph node and is 
propagated later to the spleen. It is also absent in the spleens of Il12a.Ccr7-/- mice. This 
can be attributed to the fact that CCR7 is also required for a normal spleen structure. In 
these mice, T cells were spread throughout the marginal sinuses and the red pulp in large 
clusters  (Forster et al., 1999), and are incapable of entering the periarteriolar lymphoid 
sheath (PALS) (Sharma et al., 2015). On the other hand, T cell response in the spleens 
of Xcr1-venus-DTR mice showed a robust Th1 polarization, which points out that a subset 
other than CD8α+ resident cDC1s in the spleen is taking over the antigen presentation 
and Th1 priming functions. It is possible that this is mediated by an unknown cellular 
subset that carries the apoptotic remains of the injected DCs from the draining LN through 
the blood stream to be internalized by the splenic marginal zone (Morelli and Larregina, 
2010; Morelli et al., 2003) 
4.8 Bystander activation of XCR1 migratory DCs by vaccine DCs 
While we didn’t identify the molecular interactions responsible for cDC1 communication 
with BM-DCs following immunization, 4-1BB and 4-1BBL interactions are still a likely 
candidate. A recent study reported that bystander activation of one DC to another in trans 
via 4-1BB to 4-1BBL interactions may play a role in the immune response to infection or 
vaccination, and required cell to cell contact (Macdonald et al., 2014). The use of 4-1BB 
(Kwon et al., 2002) or 4-1BBL (DeBenedette et al., 1999) deficient mice would allow 
further studies on the role of this interaction in the context of vaccine DC immunization. 
Another possible candidate that came up from the RNA sequencing dataset is Slamf7, a 
signaling lymphocytic activation molecule (SLAM) family member (Cannons et al., 2011), 
which mediates homotypic interactions with itself on adjacent cell surfaces (Li et al., 
2013). We found that it was specifically upregulated on XCR1+ migratory DCs after 
immunization. A recent report showed Slamf7 as an interacting partner for the integrin 
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CD11b (Chen et al., 2017), which is highly expressed by our injected BM-DCs suggesting 
that Slamf7-CD11b interaction is a possible route of DC-DC communication. 
We provided evidence that direct pathogen 'presentation' of LPS can induce bystander 
BM-DC activation, while CpG matured BM-DCs did not trans-activate other DCs in vitro. 
CpG activation of TLR9 within intracellular vesicles is precedes surface binding of GpG 
to DEC-205 and internalization as shown for splenic CD8+ cDC1s (Lahoud et al., 2012). 
Nevertheless, both LPS-or CpG matured BM-DCs While LPS may remain attached to the 
cell surface and could be "presented" to bystander DCs, this is largely excluded for CpG 
oligonucleotides, which are incorporated to trigger the vesicular TLR9. Since also our BM-
DCs express DEC-205 as detected by the NLDC-145 antibody (Lutz et al., 1999) the lack 
of bystander activation in vitro cannot account for a DEC-205 defect but indicates that 
other bystander mechanisms exist besides trans-activation by pathogen. 
4.9 Functional switch of XCR1 migratory DCs after bystander activation 
Here we compared the transcriptomes of steady state migratory DCs with bystander DCs. 
Steady state migratory DCs appear as a semi-mature stage with up-regulated RelB and 
surface MHC II, CD86, CD40 and CCR7 molecules but lower as compared with pathogen 
or inflammation matured migratory DCs (Azukizawa et al., 2011; Idoyaga et al., 2013; Ohl 
et al., 2004), which further up-regulate MHC and costimulation and also produce pro-
inflammatory cytokines (Ardouin et al., 2016; Voigtlander et al., 2006). The dermal steady 
state migratory cDC1 subset (ssm-cDC1), identified by expression of XCR1, CD103 and 
Langerin, has been characterized transcriptionally and revealed a matured phenotype 
with expression of RelB, IL-12p40 and CCR7 (Ardouin et al., 2016). Functionally, we 
found earlier that the ssm-cDC1s converted naive CD4+ T cells into Foxp3+ iTregs (also 
called pTregs) in a TGF- dependent manner in the skin-draining lymph nodes 
(Azukizawa et al., 2011). This TGF- signature was later confirmed at the transcriptome 
level (Ardouin et al., 2016). Also, integrin v8-dependent activation of latent TGF- 
contributes to iTreg conversion support peripheral tolerance against the self-antigens 
presented by ssm-DCs and thereby prevent auto-immunity (Travis et al., 2007). We found 
that immunogenic bystander cDC1s did not markedly up-regulate typical RNA signatures 
or markers for DC maturation over the tolerogenic ssm-cDC1 comparison. However, the 
transcriptional TGF- signature decreased. This indicates that functionally tolerogenic 
XCR1+ ssm-cDC1s may be re-programmed in the lymph node to become immunogenic 
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bystander DCs. Functional plasticity of ssm-Langerhans cells had been shown before by 
their continued capacity to internalize antigens after migration into the draining lymph 
nodes (Ruedl et al., 2001). Our previous data showed that BM-DCs that were matured 
with the inflammatory stimulus TNF maintained maturation plasticity since they could be 
further stimulated by LPS in vitro to release IL-12p70 or in vivo by endogenous stimuli 
after s.c. injection to polarize for Th1 responses (Voigtlander et al., 2006) instead of 
inducing tolerance by i.v. injection (Menges et al., 2002). Together, the transcriptional 
changes in bystander cDC1s indicate that they down-regulate steady-state functions and 
become activated to induce Th1 responses. The data provide evidence that XCR1+ 
steady state migratory cDC1s can undergo functional re-programming into bystander 
matured DCs by LPS from the migrated BM-DCs or other bystander signals sensed in the 
lymph node that appeared inflamed with increased cellularity. 
Transcriptional profiling of the XCR1+ migratory DCs showed a signature that shifts away 
from their capacity to direct Th2/Th9 and Treg polarization after BM-DC immunization. 
This was specific only for XCR1+ DCs and not observed in other migratory DC subsets. 
Interestingly, genes involved in DC migration were also down-regulated, which may 
indicate that the bystander activated DCs terminated migration to stimulate Th1 induction. 
The RelB binding partner p52 (Nfkb2) was among these genes, which we showed 
previously to be a hallmark of ssm-DCs (Ardouin et al., 2016; Azukizawa et al., 2011; 
Dohler et al., 2017). Among the up-regulated genes is Tmem79 which might be involved 
in exocytosis (Sasaki et al., 2013). The secretion by exocytosis of IL-12 is mediated by 
the SNARE family member VAMP7 (Chiaruttini et al., 2016).   
The significant increase in IL12a and IL12b gene expression by qPCR that we detected 
specifically in XCR1+ migratory DCs after BM-DC immunization was not observed in by 
RNA sequencing, we also detected a non-significant increase in IL-1β and CD80 
expression by RNA sequencing. While the low number of DCs used for sequencing can 
attribute to such a discrepancy, it is also possible that the bystander activation signal was 
diluted by the remaining steady-state XCR1+ migratory cDC1s that still carry out their 
tolerogenic functions. Such a heterogeneity has been observed by single cell sequencing 
among LPS-stimulated spleen cells where the DCs clustered differently when compared 
to the existing marker-based classification (Jaitin et al., 2014). Using our defined 
transcriptional signature for bystander activated XCR1+ migratory cDC1s, it might be 
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possible to distinguish them from their steady-state counterpart and specifically target 
them for enhancing DC vaccination protocols.  
 
In conclusion, our data suggest that Th1 priming by DC vaccination requires endogenous 
bystander DCs for antigen presentation and IL-12p70 production. The time kinetic 
experiments suggest a strict requirement for the injected BM-DCs for Th0 priming 
preceding the bystander DC activation and IL-12 production. Only the CCR7+ migratory 
but not resident fraction of the XCR1+ cDC1 subset acquired bystander function. These 
findings are of translational importance for human DC vaccination studies in immuno-
compromised tumor patients where the bystander DC activity may be impaired. The 
dissemination of the systemic response and the exact molecular mechanisms driving the 
endogenous bystander migratory XCR1+ cDC1 activation are two important points that 
need further studying. 
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EBI2 Epstein-Barr virus induced 2 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence acquired cell sorting 
Fc Fragment crystallisable 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
Flt3-L Fms-like tyrosine kinase 3 ligand 
FSC Forward scatter 
Fwd Forward 
g Gram 
GATA-3 GATA binding protein 3 
GEO Gene Expression Omnibus 
GM-CSF Granulocyte/macrophage colony-stimulating factor 
h Hours 
i.p. intraperitoneal 
 
112 
 
 
i.v. intravenous 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
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